{"id":419001,"date":"2026-03-18T23:22:00","date_gmt":"2026-03-18T15:22:00","guid":{"rendered":"https:\/\/pingtungtimes.com.tw\/?p=419001"},"modified":"2026-03-18T23:22:00","modified_gmt":"2026-03-18T15:22:00","slug":"%e7%b8%bd%e7%94%9f%e5%ad%98%e6%9c%9f%e9%a1%af%e8%91%97%e5%bb%b6%e9%95%b7%ef%bc%9a%e8%98%86%e5%ba%b7%e6%b2%99%e5%a6%a5%e7%8f%a0%e5%96%ae%e6%8a%97sac-tmt-optitrop-lung03%e7%a0%94%e7%a9%b6os%e6%9c%80","status":"publish","type":"post","link":"https:\/\/pingtungtimes.com.tw\/?p=419001","title":{"rendered":"\u7e3d\u751f\u5b58\u671f\u986f\u8457\u5ef6\u9577\uff1a\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT) OptiTROP-Lung03\u7814\u7a76OS\u6700\u7d42\u5206\u6790\u7d50\u679c\u4eae\u76f8"},"content":{"rendered":"
\n\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u6210\u90fd<\/span>2026\u5e743\u670818\u65e5<\/span> \/\u7f8e\u901a\u793e\/ — 2026\u5e74\u6b50\u6d32\u80ba\u764c\u5927\u6703(ELCC)\u5c07\u65bc\u7576\u5730\u6642\u95933\u670825\u65e5\u81f328\u65e5\u5728\u4e39\u9ea5\u54e5\u672c\u54c8\u6839\u8209\u884c\u3002\u672c\u6b21\u6703\u8b70\u4e0a\uff0c\u56db\u5ddd\u79d1\u502b\u535a\u6cf0\u751f\u7269\u91ab\u85e5\u80a1\u4efd\u6709\u9650\u516c\u53f8(\u300c\u79d1\u502b\u535a\u6cf0\u300d\u6216\u300c\u516c\u53f8\u300d\uff0c6990.HK)\u81ea\u4e3b\u7814\u767c\u7684TROP2 ADC\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297( sac-TMT\uff0c\u4ea6\u7a31SKB264\/MK-2870)(\u4f73\u6cf0\u840a\u00ae<\/sup>)\u95dc\u9375\u81e8\u5e8a\u7814\u7a76(OptiTROP-Lung03)\u7684OS\u6700\u7d42\u5206\u6790\u7d50\u679c\u6210\u529f\u5165\u9078\u7a81\u7834\u6027\u6458\u8981<\/b>(LBA)<\/b>(\u5831\u544a\u7de8\u865f\uff1aLBA4)\uff0c\u5c46\u6642\u5c07\u7531\u4e2d\u5c71\u5927\u5b78\u816b\u7624\u9632\u6cbb\u4e2d\u5fc3\u694a\u96f2\u9d6c\u6559\u6388<\/b>\u5728\u5c0f\u578b\u53e3\u982d\u5831\u544a\u5c08\u5834\uff08Mini Oral Session\uff09\u5411\u5168\u7403\u5b78\u8005\u5f59\u5831\u5206\u4eab\uff0c\u6458\u8981\u5df2\u767c\u4f48\u65bcESMO Open<\/i>\u671f\u520a\u3002<\/p>\n

\n

<\/span><\/p>\n<\/p><\/div>\n

OptiTROP-Lung03\u7814\u7a76\u65e8\u5728\u8a55\u4f30\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u55ae\u4e00\u7642\u6cd5(5 mg\/kg\u6bcf2\u9031\u4e00\u6b21) \u5c0d\u6bd4\u591a\u897f\u4ed6\u8cfd\uff0c\u5728\u65e2\u5f80\u63a5\u53d7\u904eEGFR-TKI\u548c\u542b\u9251\u5316\u7642\u6cbb\u7642\u7684\u5c40\u90e8\u665a\u671f\u6216\u8f49\u79fb\u6027EGFR\u7a81\u8b8a\u975e\u5c0f\u7d30\u80de\u80ba\u764c(NSCLC)\u60a3\u8005\u4e2d\u7684\u6709\u6548\u6027\u548c\u5b89\u5168\u6027\u3002\u6b64\u524d\u57282025\u5e74ASCO\u5e74\u6703\u4e0a\u516c\u4f48\u7684\u7d50\u679c\u986f\u793a\uff0c\u5728137\u4f8b\u96a8\u6a5f\u5165\u7d44\u7684\u60a3\u8005\u4e2d\uff0c\u76f8\u8f03\u65bc\u591a\u897f\u4ed6\u8cfd\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u5728\u7121\u9032\u5c55\u751f\u5b58\u671f(PFS\uff09\u548c\u7e3d\u751f\u5b58\u671f(OS)\u65b9\u9762\u5177\u6709\u986f\u8457\u7d71\u8a08\u5b78\u610f\u7fa9\u548c\u81e8\u5e8a\u610f\u7fa9\u7684\u6539\u5584\u2014\u2014\u7d93BICR\u8a55\u4f30\u7684PFS\u98a8\u96aa\u6bd4(HR)\u70ba0.30(95% CI: 0.20-0.46, \u55ae\u5074p<0.001)\uff1bOS\u7684HR\u70ba0.49(95% CI: 0.27-0.88, \u55ae\u5074p=0.007)[1]<\/sup>\u3002\u57fa\u65bc\u9019\u4e00\u7a4d\u6975\u7d50\u679c\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u7372\u570b\u5bb6\u85e5\u54c1\u76e3\u7763\u7ba1\u7406\u5c40(NMPA)\u6279\u51c6\u6b64\u9069\u61c9\u75c7\uff0c\u8a72\u9069\u61c9\u75c7\u5df2\u88ab\u7d0d\u5165\u570b\u5bb6\u91ab\u4fdd\u76ee\u9304\u3002<\/p>\n

2026 ELCC\u6703\u8b70\u5c07\u516c\u4f48OptiTROP-Lung03\u7814\u7a76\u7684OS<\/b>\u6700\u7d42\u5206\u6790\u7d50\u679c\u53ca\u66f4\u65b0\u7684<\/b>PFS<\/b>\u8cc7\u6599\u7b49<\/b>(\u622a\u81f32025\u5e7412\u670811\u65e5\uff0c\u4e2d\u4f4d\u96a8\u8a2a\u6642\u9593\u70ba23.8\u500b\u6708)\uff0c\u4e3b\u8981\u5167\u5bb9\u5982\u4e0b\uff1a<\/span><\/p>\n

    \n
  • \u591a\u897f\u4ed6\u8cfd\u6cbb\u7642\u5c0d\u7167\u7d44\uff0c\u670941.3%\u7684\u60a3\u8005\u5728\u75be\u75c5\u9032\u5c55\u5f8c\u9078\u64c7\u63a5\u53d7\u4e86\u5f8c\u7e8c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u6cbb\u7642\u3002<\/li>\n
  • \u8003\u616e\u5c0d\u7167\u7d44\u4ea4\u53c9\u6cbb\u7642\u5c0dOS\u5f71\u97ff\uff0c\u63a1\u7528\u9810\u8a2d\u7684\u79e9\u4fdd\u6301\u7d50\u69cb\u5931\u6548\u6642\u9593(RPSFT)\u6a21\u578b\u9032\u884c\u6821\u6b63\u5206\u6790\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u7d44\u8207\u591a\u897f\u4ed6\u8cfd\u7d44\u4e2d\u4f4dOS\u5206\u5225\u70ba20.0\u500b\u6708 vs 11.2\u500b\u6708(HR 0.45, 95% CI : 0.28-0.73)\uff0c18\u500b\u6708OS\u7387\u5206\u5225\u70ba54.7% vs 9.1%\uff1b<\/span><\/b> \u82e5\u5c0d\u7167\u7d44OS\u4e0d\u7d93\u5f8c\u7e8csac-TMT\u6cbb\u7642\u6821\u6b63\uff0c\u5169\u7d44\u7684\u4e2d\u4f4dOS\u5247\u70ba20.0\u500b\u6708 vs 13.5\u500b\u6708(HR 0.63, 95% CI: 0.40-0.98)\uff1b<\/li>\n
  • \u7814\u7a76\u8005(INV)\u8a55\u4f30\u7684\u4e2d\u4f4dPFS\u70ba7.9\u500b\u6708 vs 2.8\u500b\u6708(HR 0.23, 95% CI: 0.15-0.35)\u3002<\/li>\n<\/ul>\n

    \u503c\u5f97\u4e00\u63d0\u7684\u662f\uff0c\u57fa\u65bc\u53e6\u5916\u4e00\u9805OptiTROP-Lung04\u7814\u7a76\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT) \u5df2\u7372NMPA\u6279\u51c6\u7528\u65bc\u7d93EGFR-TKI\u6cbb\u7642\u5f8c\u9032\u5c55\u7684\u665a\u671f\u6216\u8f49\u79fb\u6027EGFR\u7a81\u8b8aNSCLC, \u76f8\u95dc\u7d50\u679c\u5df2\u540c\u6b65\u767c\u8868\u65bc\u300a\u65b0\u82f1\u683c\u862d\u91ab\u5b78\u96dc\u8a8c\u300b[2]<\/sup>\u3002\u800c\u6b64\u6b21\u5728\u7d93EGFR-TKI\u548c\u542b\u9251\u5316\u7642\u6cbb\u7642\u5f8c\u9032\u5c55\u7684EGFRm NSCLC\u4eba\u7fa4\u4e2d\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297\u53d6\u5f97\u4e86\u5177\u6709\u986f\u8457\u7d71\u8a08\u5b78\u610f\u7fa9\u548c\u81e8\u5e8a\u610f\u7fa9\u7684\u751f\u5b58\u7372\u76ca\uff0c\u4e2d\u4f4d<\/b>OS<\/b>\u9577\u9054<\/b>20<\/b>\u500b\u6708\u3002<\/b>\u5169\u9805\u95dc\u9375\u8a3b\u518a\u7814\u7a76\u7684\u76f8\u7e7c\u9a57\u8b49\uff0c\u9032\u4e00\u6b65\u78ba\u7acb\u4e86\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u5728\u7d93\u6cbbEGFR\u7a81\u8b8aNSCLC\u6cbb\u7642\u9818\u57df\u7684\u9818\u5148\u5730\u4f4d\uff0c\u70ba\u665a\u671f\u80ba\u764c\u60a3\u8005\u63d0\u4f9b\u4e86\u66f4\u5177\u78ba\u5b9a\u6027\u8207\u9577\u671f\u751f\u5b58\u7372\u76ca\u7684\u6cbb\u7642\u9078\u64c7\u3002<\/p>\n

    \u95dc\u65bc\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297<\/u><\/b>(sac-TMT)(<\/u><\/b>\u4f73\u6cf0\u840a<\/u><\/b>\u00ae<\/sup><\/u><\/b>)<\/u><\/b><\/p>\n

    \u4f5c\u70ba\u516c\u53f8\u7684\u6838\u5fc3\u7522\u54c1\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u662f\u4e00\u6b3e\u516c\u53f8\u64c1\u6709\u81ea\u4e3b\u667a\u6167\u8ca1\u7522\u6b0a\u7684\u65b0\u578bTROP2 ADC\uff0c\u91dd\u5c0dNSCLC\u3001\u4e73\u817a\u764c(BC)\u3001\u80c3\u764c(GC)\u3001\u5a66\u79d1\u816b\u7624\u7b49\u665a\u671f\u5be6\u9ad4\u7624\u3002\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u63a1\u7528\u65b0\u578b\u9023\u63a5\u5b50\u9032\u884c\u958b\u767c\uff0c\u5176\u901a\u904e\u5076\u806f\u4e00\u7a2e\u8c9d\u6d1b\u66ff\u5eb7\u884d\u751f\u7684\u62d3\u64b2\u7570\u69cb\u9176I\u6291\u5236\u5291\u4f5c\u70ba\u6709\u6548\u8f09\u8377\uff0c\u85e5\u7269\u6297\u9ad4\u6bd4(DAR)\u9054\u52307.4\u3002\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u901a\u904e\u91cd\u7d44\u6297TROP2\u4eba\u6e90\u5316\u55ae\u514b\u9686\u6297\u9ad4\u7279\u7570\u6027\u8b58\u5225\u816b\u7624\u7d30\u80de\u8868\u9762\u7684TROP2\uff0c\u5176\u5f8c\u88ab\u816b\u7624\u7d30\u80de\u5167\u541e\u4f75\u65bc\u7d30\u80de\u5167\u91cb\u653e\u6709\u6548\u8f09\u8377KL610023\u3002KL610023\u4f5c\u70ba\u62d3\u64b2\u7570\u69cb\u9176I\u6291\u5236\u5291\uff0c\u53ef\u8a98\u5c0e\u816b\u7624\u7d30\u80deDNA\u640d\u50b7\uff0c\u9032\u800c\u5c0e\u81f4\u7d30\u80de\u9031\u671f\u963b\u6eef\u53ca\u7d30\u80de\u51cb\u4ea1\u3002\u6b64\u5916\uff0c\u5176\u4ea6\u65bc\u816b\u7624\u5fae\u74b0\u5883\u4e2d\u91cb\u653eKL610023\u3002\u9452\u65bcKL610023\u5177\u6709\u7d30\u80de\u819c\u6ef2\u900f\u6027\uff0c\u5176\u53ef\u5be6\u73fe\u65c1\u89c0\u8005\u6548\u61c9\uff0c\u5373\u6bba\u6b7b\u9130\u8fd1\u7684\u816b\u7624\u7d30\u80de\u3002<\/p>\n

    \u65bc2022\u5e745\u6708\uff0c\u516c\u53f8\u6388\u4e88\u9ed8\u6c99\u6771(\u7f8e\u570b\u65b0\u6fa4\u897f\u5dde\u7f85\u5a01\u5e02\u9ed8\u514b\u516c\u53f8\u7684\u5546\u865f)\u5728\u5927\u4e2d\u83ef\u5340(\u5305\u62ec\u4e2d\u570b\u5167\u5730\u3001\u9999\u6e2f\u3001\u6fb3\u9580\u53ca\u81fa\u7063)\u4ee5\u5916\u7684\u6240\u6709\u5730\u5340\u958b\u767c\u3001\u4f7f\u7528\u3001\u88fd\u9020\u53ca\u5546\u696d\u5316\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u7684\u7368\u5bb6\u6b0a\u5229\u3002<\/p>\n

    \u622a\u81f3\u76ee\u524d\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u76844\u9805\u9069\u61c9\u75c7\u5df2\u65bc\u4e2d\u570b\u7372\u6279\u4e0a\u5e02\uff0c\u5206\u5225\u7528\u65bc\uff1a\u7d93EGFR-TKI\u548c\u542b\u9251\u5316\u7642\u6cbb\u7642\u5f8c\u9032\u5c55\u7684EGFR\u57fa\u56e0\u7a81\u8b8a\u967d\u6027\u7684\u5c40\u90e8\u665a\u671f\u6216\u8f49\u79fb\u6027\u975e\u9c57\u72c0NSCLC\uff1b\u65e2\u5f80\u81f3\u5c11\u63a5\u53d7\u904e2\u7a2e\u7cfb\u7d71\u6cbb\u7642\uff08\u5176\u4e2d\u81f3\u5c111\u7a2e\u6cbb\u7642\u91dd\u5c0d\u665a\u671f\u6216\u8f49\u79fb\u6027\u968e\u6bb5\uff09\u7684\u4e0d\u53ef\u5207\u9664\u7684\u5c40\u90e8\u665a\u671f\u6216\u8f49\u79fb\u6027TNBC\uff1b\u7d93EGFR-TKI\u6cbb\u7642\u5f8c\u9032\u5c55\u7684EGFR\u57fa\u56e0\u7a81\u8b8a\u967d\u6027\u7684\u5c40\u90e8\u665a\u671f\u6216\u8f49\u79fb\u6027\u975e\u9c57\u72c0NSCLC\uff1b\u65e2\u5f80\u63a5\u53d7\u904e\u5167\u5206\u6ccc\u6cbb\u7642\u4e14\u5728\u665a\u671f\u75be\u75c5\u968e\u6bb5\u63a5\u53d7\u904e\u81f3\u5c11\u4e00\u7dda\u5316\u7642\u7684\u4e0d\u53ef\u5207\u9664\u6216\u8f49\u79fb\u6027\u7684HR+\/HER2- (IHC 0\u3001IHC 1+\u6216IHC 2+\/ISH-) BC\uff1b\u5176\u4e2d\u524d2\u9805\u9069\u61c9\u75c7\u5df2\u7d93\u88ab\u7d0d\u5165\u91ab\u4fdd\u7bc4\u570d\uff0c\u5c07\u70ba\u66f4\u591a\u4e73\u817a\u764c\u548c\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u60a3\u8005\u5e36\u4f86\u81e8\u5e8a\u7372\u76ca\u3002\u6b64\u5916\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u5df2\u7372NMPA\u6388\u4e886\u9805\u7a81\u7834\u6027\u7642\u6cd5\u8a8d\u5b9a(BTD)\u3002<\/p>\n

    \u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u662f\u5168\u7403\u9996\u500b\u5728\u80ba\u764c\u9069\u61c9\u75c7\u7372\u6279\u4e0a\u5e02\u7684TROP2 ADC\u85e5\u7269\u3002\u76ee\u524d\uff0c\u79d1\u502b\u535a\u6cf0\u5df2\u5728\u4e2d\u570b\u958b\u5c559\u9805\u8a3b\u518a\u6027\u81e8\u5e8a\u7814\u7a76\u3002\u9ed8\u6c99\u6771\u5df2\u4f48\u5c4017\u9805\u6b63\u5728\u9032\u884c\u7684\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u4f5c\u70ba\u55ae\u85e5\u7642\u6cd5\u6216\u806f\u5408\u5e15\u535a\u5229\u73e0\u55ae\u6297\u6216\u5176\u4ed6\u6297\u764c\u85e5\u7269\u7528\u65bc\u591a\u7a2e\u985e\u578b\u764c\u75c7\u7684\u5168\u7403\u6027III\u671f\u81e8\u5e8a\u7814\u7a76(\u9019\u4e9b\u7814\u7a76\u7531\u9ed8\u6c99\u6771\u7533\u8fa6\u4e26\u4e3b\u5c0e)\u3002<\/p>\n

    \u95dc\u65bc\u79d1\u502b\u535a\u6cf0<\/u><\/b><\/p>\n

    \u56db\u5ddd\u79d1\u502b\u535a\u6cf0\u751f\u7269\u91ab\u85e5\u80a1\u4efd\u6709\u9650\u516c\u53f8(\u7c21\u7a31\u300c\u79d1\u502b\u535a\u6cf0\u300d\uff0c\u80a1\u7968\u4ee3\u78bc\uff1a6990.HK)\u662f\u79d1\u502b\u85e5\u696d\u63a7\u80a1\u5b50\u516c\u53f8\uff0c\u5c08\u6ce8\u4e8e\u5275\u65b0\u751f\u7269\u6280\u8853\u85e5\u7269\u53ca\u5c0f\u5206\u5b50\u85e5\u7269\u7684\u7814\u767c\u3001\u751f\u7522\u3001\u5546\u696d\u5316\u53ca\u570b\u969b\u5408\u4f5c\u3002\u516c\u53f8\u570d\u7e5e\u5168\u7403\u548c\u4e2d\u570b\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\uff0c\u91cd\u9ede\u4f48\u5c40\u816b\u7624\u3001\u81ea\u8eab\u514d\u75ab\u548c\u4ee3\u8b1d\u7b49\u91cd\u5927\u75be\u75c5\u9818\u57df\uff0c\u5efa\u8a2d\u570b\u969b\u5316\u85e5\u7269\u7814\u767c\u8207\u7522\u696d\u5316\u5e73\u81fa\uff0c\u81f4\u529b\u65bc\u6210\u70ba\u5728\u5275\u65b0\u85e5\u7269\u9818\u57df\u570b\u969b\u9818\u5148\u7684\u4f01\u696d\u3002\u516c\u53f8\u76ee\u524d\u64c1\u670930\u4f59\u500b\u91cd\u9ede\u5275\u65b0\u85e5\u9805\u76ee\uff0c\u5176\u4e2d4\u500b\u9805\u76ee8\u500b\u9069\u61c9\u75c7\u5df2\u7372\u6279\u4e0a\u5e02\uff0c1\u500b\u5c08\u6848\u8655\u65bcNDA\u968e\u6bb5\uff0c10\u9918\u500b\u5c08\u6848\u6b63\u8655\u65bc\u81e8\u5e8a\u968e\u6bb5\u3002\u516c\u53f8\u6210\u529f\u69cb\u5efa\u4e86\u4eab\u8b7d\u570b\u969b\u7684\u5c08\u6709ADC\u53ca\u65b0\u578b\u5076\u806f\u85e5\u7269\u5e73\u81faOptiDCTM<\/sup>\uff0c\u5df2\u67092\u500bADC\u9805\u76ee5\u500b\u9069\u61c9\u75c7\u7372\u6279\u4e0a\u5e02\uff0c\u591a\u500bADC\u6216\u65b0\u578b\u5076\u806f\u85e5\u7269\u7522\u54c1\u8655\u65bc\u81e8\u5e8a\u6216\u81e8\u5e8a\u524d\u7814\u7a76\u968e\u6bb5\u3002<\/p>\n

    \u53c3\u8003\u4f86\u6e90\uff1a
    [1] Fang W, Li X, Wang Q, et al. Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutant advanced non-small-cell lung cancer: open label, randomised, multicentre trial[J]. BMJ. 2025 Jun 5:389:e085680. doi: 10.1136\/bmj-2025-085680.
    [2] Fang W, Wu L, Meng X, et al. Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR-Mutated Advanced NSCLC[J]. NEJM. 2026 Jan 1;394(1):13-26. doi: 10.1056\/NEJMoa2512071. Epub 2025 Oct 19.<\/p>\n

    \n<\/p><\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

    \u6210\u90fd2026\u5e743\u670818\u65e5 \/\u7f8e…<\/p>\n","protected":false},"author":16,"featured_media":419002,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"fifu_image_url":"","fifu_image_alt":"","footnotes":""},"categories":[40567],"tags":[],"class_list":["post-419001","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-40567"],"acf":[],"yoast_head":"\n\u7e3d\u751f\u5b58\u671f\u986f\u8457\u5ef6\u9577\uff1a\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT) OptiTROP-Lung03\u7814\u7a76OS\u6700\u7d42\u5206\u6790\u7d50\u679c\u4eae\u76f8 - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831<\/title>\n<meta name=\"description\" content=\"\u6210\u90fd2026\u5e743\u670818\u65e5 \/\u7f8e\u901a\u793e\/ -- 2026\u5e74\u6b50\u6d32\u80ba\u764c\u5927\u6703(ELCC)\u5c07\u65bc\u7576\u5730\u6642\u95933\u670825\u65e5\u81f328\u65e5\u5728\u4e39\u9ea5\u54e5\u672c\u54c8\u6839\u8209\u884c\u3002\u672c\u6b21\u6703\u8b70\u4e0a\uff0c\u56db\u5ddd\u79d1\u502b\u535a\u6cf0\u751f\u7269\u91ab\u85e5\u80a1\u4efd\u6709\u9650\u516c\u53f8(\u300c\u79d1\u502b\u535a\u6cf0\u300d\u6216\u300c\u516c\u53f8\u300d\uff0c6990.HK)\u81ea\u4e3b\u7814\u767c\u7684TROP2 ADC\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297( sac-TMT\uff0c\u4ea6\u7a31SKB264\/MK-2870)(\u4f73\u6cf0\u840a\u00ae)\u95dc\u9375\u81e8\u5e8a\u7814\u7a76(OptiTROP-Lung03)\u7684OS\u6700\u7d42\u5206\u6790\u7d50\u679c\u6210\u529f\u5165\u9078\u7a81\u7834\u6027\u6458\u8981(LBA)(\u5831\u544a\u7de8\u865f\uff1aLBA4)\uff0c\u5c46\u6642\u5c07\u7531\u4e2d\u5c71\u5927\u5b78\u816b\u7624\u9632\u6cbb\u4e2d\u5fc3\u694a\u96f2\u9d6c\u6559\u6388\u5728\u5c0f\u578b\u53e3\u982d\u5831\u544a\u5c08\u5834\uff08Mini Oral Session\uff09\u5411\u5168\u7403\u5b78\u8005\u5f59\u5831\u5206\u4eab\uff0c\u6458\u8981\u5df2\u767c\u4f48\u65bcESMO Open\u671f\u520a\u3002 OptiTROP-Lung03\u7814\u7a76\u65e8\u5728\u8a55\u4f30\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u55ae\u4e00\u7642\u6cd5(5 mg\/kg\u6bcf2\u9031\u4e00\u6b21) \u5c0d\u6bd4\u591a\u897f\u4ed6\u8cfd\uff0c\u5728\u65e2\u5f80\u63a5\u53d7\u904eEGFR-TKI\u548c\u542b\u9251\u5316\u7642\u6cbb\u7642\u7684\u5c40\u90e8\u665a\u671f\u6216\u8f49\u79fb\u6027EGFR\u7a81\u8b8a\u975e\u5c0f\u7d30\u80de\u80ba\u764c(NSCLC)\u60a3\u8005\u4e2d\u7684\u6709\u6548\u6027\u548c\u5b89\u5168\u6027\u3002\u6b64\u524d\u57282025\u5e74ASCO\u5e74\u6703\u4e0a\u516c\u4f48\u7684\u7d50\u679c\u986f\u793a\uff0c\u5728137\u4f8b\u96a8\u6a5f\u5165\u7d44\u7684\u60a3\u8005\u4e2d\uff0c\u76f8\u8f03\u65bc\u591a\u897f\u4ed6\u8cfd\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u5728\u7121\u9032\u5c55\u751f\u5b58\u671f(PFS\uff09\u548c\u7e3d\u751f\u5b58\u671f(OS)\u65b9\u9762\u5177\u6709\u986f\u8457\u7d71\u8a08\u5b78\u610f\u7fa9\u548c\u81e8\u5e8a\u610f\u7fa9\u7684\u6539\u5584\u2014\u2014\u7d93BICR\u8a55\u4f30\u7684PFS\u98a8\u96aa\u6bd4(HR)\u70ba0.30(95% CI: 0.20-0.46, \u55ae\u5074p<0.001)\uff1bOS\u7684HR\u70ba0.49(95% CI: 0.27-0.88, \u55ae\u5074p=0.007)\u3002\u57fa\u65bc\u9019\u4e00\u7a4d\u6975\u7d50\u679c\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u7372\u570b\u5bb6\u85e5\u54c1\u76e3\u7763\u7ba1\u7406\u5c40(NMPA)\u6279\u51c6\u6b64\u9069\u61c9\u75c7\uff0c\u8a72\u9069\u61c9\u75c7\u5df2\u88ab\u7d0d\u5165\u570b\u5bb6\u91ab\u4fdd\u76ee\u9304\u3002 2026 ELCC\u6703\u8b70\u5c07\u516c\u4f48OptiTROP-Lung03\u7814\u7a76\u7684OS\u6700\u7d42\u5206\u6790\u7d50\u679c\u53ca\u66f4\u65b0\u7684PFS\u8cc7\u6599\u7b49(\u622a\u81f32025\u5e7412\u670811\u65e5\uff0c\u4e2d\u4f4d\u96a8\u8a2a\u6642\u9593\u70ba23.8\u500b\u6708)\uff0c\u4e3b\u8981\u5167\u5bb9\u5982\u4e0b\uff1a \u591a\u897f\u4ed6\u8cfd\u6cbb\u7642\u5c0d\u7167\u7d44\uff0c\u670941.3%\u7684\u60a3\u8005\u5728\u75be\u75c5\u9032\u5c55\u5f8c\u9078\u64c7\u63a5\u53d7\u4e86\u5f8c\u7e8c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u6cbb\u7642\u3002 \u8003\u616e\u5c0d\u7167\u7d44\u4ea4\u53c9\u6cbb\u7642\u5c0dOS\u5f71\u97ff\uff0c\u63a1\u7528\u9810\u8a2d\u7684\u79e9\u4fdd\u6301\u7d50\u69cb\u5931\u6548\u6642\u9593(RPSFT)\u6a21\u578b\u9032\u884c\u6821\u6b63\u5206\u6790\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u7d44\u8207\u591a\u897f\u4ed6\u8cfd\u7d44\u4e2d\u4f4dOS\u5206\u5225\u70ba20.0\u500b\u6708 vs 11.2\u500b\u6708(HR 0.45, 95% CI : 0.28-0.73)\uff0c18\u500b\u6708OS\u7387\u5206\u5225\u70ba54.7% vs 9.1%\uff1b \u82e5\u5c0d\u7167\u7d44OS\u4e0d\u7d93\u5f8c\u7e8csac-TMT\u6cbb\u7642\u6821\u6b63\uff0c\u5169\u7d44\u7684\u4e2d\u4f4dOS\u5247\u70ba20.0\u500b\u6708 vs 13.5\u500b\u6708(HR 0.63, 95% CI: 0.40-0.98)\uff1b \u7814\u7a76\u8005(INV)\u8a55\u4f30\u7684\u4e2d\u4f4dPFS\u70ba7.9\u500b\u6708 vs 2.8\u500b\u6708(HR 0.23, 95% CI: 0.15-0.35)\u3002 \u503c\u5f97\u4e00\u63d0\u7684\u662f\uff0c\u57fa\u65bc\u53e6\u5916\u4e00\u9805OptiTROP-Lung04\u7814\u7a76\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT) \u5df2\u7372NMPA\u6279\u51c6\u7528\u65bc\u7d93EGFR-TKI\u6cbb\u7642\u5f8c\u9032\u5c55\u7684\u665a\u671f\u6216\u8f49\u79fb\u6027EGFR\u7a81\u8b8aNSCLC, \u76f8\u95dc\u7d50\u679c\u5df2\u540c\u6b65\u767c\u8868\u65bc\u300a\u65b0\u82f1\u683c\u862d\u91ab\u5b78\u96dc\u8a8c\u300b\u3002\u800c\u6b64\u6b21\u5728\u7d93EGFR-TKI\u548c\u542b\u9251\u5316\u7642\u6cbb\u7642\u5f8c\u9032\u5c55\u7684EGFRm NSCLC\u4eba\u7fa4\u4e2d\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297\u53d6\u5f97\u4e86\u5177\u6709\u986f\u8457\u7d71\u8a08\u5b78\u610f\u7fa9\u548c\u81e8\u5e8a\u610f\u7fa9\u7684\u751f\u5b58\u7372\u76ca\uff0c\u4e2d\u4f4dOS\u9577\u905420\u500b\u6708\u3002\u5169\u9805\u95dc\u9375\u8a3b\u518a\u7814\u7a76\u7684\u76f8\u7e7c\u9a57\u8b49\uff0c\u9032\u4e00\u6b65\u78ba\u7acb\u4e86\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u5728\u7d93\u6cbbEGFR\u7a81\u8b8aNSCLC\u6cbb\u7642\u9818\u57df\u7684\u9818\u5148\u5730\u4f4d\uff0c\u70ba\u665a\u671f\u80ba\u764c\u60a3\u8005\u63d0\u4f9b\u4e86\u66f4\u5177\u78ba\u5b9a\u6027\u8207\u9577\u671f\u751f\u5b58\u7372\u76ca\u7684\u6cbb\u7642\u9078\u64c7\u3002 \u95dc\u65bc\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)(\u4f73\u6cf0\u840a\u00ae) \u4f5c\u70ba\u516c\u53f8\u7684\u6838\u5fc3\u7522\u54c1\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u662f\u4e00\u6b3e\u516c\u53f8\u64c1\u6709\u81ea\u4e3b\u667a\u6167\u8ca1\u7522\u6b0a\u7684\u65b0\u578bTROP2 ADC\uff0c\u91dd\u5c0dNSCLC\u3001\u4e73\u817a\u764c(BC)\u3001\u80c3\u764c(GC)\u3001\u5a66\u79d1\u816b\u7624\u7b49\u665a\u671f\u5be6\u9ad4\u7624\u3002\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u63a1\u7528\u65b0\u578b\u9023\u63a5\u5b50\u9032\u884c\u958b\u767c\uff0c\u5176\u901a\u904e\u5076\u806f\u4e00\u7a2e\u8c9d\u6d1b\u66ff\u5eb7\u884d\u751f\u7684\u62d3\u64b2\u7570\u69cb\u9176I\u6291\u5236\u5291\u4f5c\u70ba\u6709\u6548\u8f09\u8377\uff0c\u85e5\u7269\u6297\u9ad4\u6bd4(DAR)\u9054\u52307.4\u3002\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u901a\u904e\u91cd\u7d44\u6297TROP2\u4eba\u6e90\u5316\u55ae\u514b\u9686\u6297\u9ad4\u7279\u7570\u6027\u8b58\u5225\u816b\u7624\u7d30\u80de\u8868\u9762\u7684TROP2\uff0c\u5176\u5f8c\u88ab\u816b\u7624\u7d30\u80de\u5167\u541e\u4f75\u65bc\u7d30\u80de\u5167\u91cb\u653e\u6709\u6548\u8f09\u8377KL610023\u3002KL610023\u4f5c\u70ba\u62d3\u64b2\u7570\u69cb\u9176I\u6291\u5236\u5291\uff0c\u53ef\u8a98\u5c0e\u816b\u7624\u7d30\u80deDNA\u640d\u50b7\uff0c\u9032\u800c\u5c0e\u81f4\u7d30\u80de\u9031\u671f\u963b\u6eef\u53ca\u7d30\u80de\u51cb\u4ea1\u3002\u6b64\u5916\uff0c\u5176\u4ea6\u65bc\u816b\u7624\u5fae\u74b0\u5883\u4e2d\u91cb\u653eKL610023\u3002\u9452\u65bcKL610023\u5177\u6709\u7d30\u80de\u819c\u6ef2\u900f\u6027\uff0c\u5176\u53ef\u5be6\u73fe\u65c1\u89c0\u8005\u6548\u61c9\uff0c\u5373\u6bba\u6b7b\u9130\u8fd1\u7684\u816b\u7624\u7d30\u80de\u3002 \u65bc2022\u5e745\u6708\uff0c\u516c\u53f8\u6388\u4e88\u9ed8\u6c99\u6771(\u7f8e\u570b\u65b0\u6fa4\u897f\u5dde\u7f85\u5a01\u5e02\u9ed8\u514b\u516c\u53f8\u7684\u5546\u865f)\u5728\u5927\u4e2d\u83ef\u5340(\u5305\u62ec\u4e2d\u570b\u5167\u5730\u3001\u9999\u6e2f\u3001\u6fb3\u9580\u53ca\u81fa\u7063)\u4ee5\u5916\u7684\u6240\u6709\u5730\u5340\u958b\u767c\u3001\u4f7f\u7528\u3001\u88fd\u9020\u53ca\u5546\u696d\u5316\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u7684\u7368\u5bb6\u6b0a\u5229\u3002 \u622a\u81f3\u76ee\u524d\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u76844\u9805\u9069\u61c9\u75c7\u5df2\u65bc\u4e2d\u570b\u7372\u6279\u4e0a\u5e02\uff0c\u5206\u5225\u7528\u65bc\uff1a\u7d93EGFR-TKI\u548c\u542b\u9251\u5316\u7642\u6cbb\u7642\u5f8c\u9032\u5c55\u7684EGFR\u57fa\u56e0\u7a81\u8b8a\u967d\u6027\u7684\u5c40\u90e8\u665a\u671f\u6216\u8f49\u79fb\u6027\u975e\u9c57\u72c0NSCLC\uff1b\u65e2\u5f80\u81f3\u5c11\u63a5\u53d7\u904e2\u7a2e\u7cfb\u7d71\u6cbb\u7642\uff08\u5176\u4e2d\u81f3\u5c111\u7a2e\u6cbb\u7642\u91dd\u5c0d\u665a\u671f\u6216\u8f49\u79fb\u6027\u968e\u6bb5\uff09\u7684\u4e0d\u53ef\u5207\u9664\u7684\u5c40\u90e8\u665a\u671f\u6216\u8f49\u79fb\u6027TNBC\uff1b\u7d93EGFR-TKI\u6cbb\u7642\u5f8c\u9032\u5c55\u7684EGFR\u57fa\u56e0\u7a81\u8b8a\u967d\u6027\u7684\u5c40\u90e8\u665a\u671f\u6216\u8f49\u79fb\u6027\u975e\u9c57\u72c0NSCLC\uff1b\u65e2\u5f80\u63a5\u53d7\u904e\u5167\u5206\u6ccc\u6cbb\u7642\u4e14\u5728\u665a\u671f\u75be\u75c5\u968e\u6bb5\u63a5\u53d7\u904e\u81f3\u5c11\u4e00\u7dda\u5316\u7642\u7684\u4e0d\u53ef\u5207\u9664\u6216\u8f49\u79fb\u6027\u7684HR+\/HER2- (IHC 0\u3001IHC 1+\u6216IHC 2+\/ISH-) BC\uff1b\u5176\u4e2d\u524d2\u9805\u9069\u61c9\u75c7\u5df2\u7d93\u88ab\u7d0d\u5165\u91ab\u4fdd\u7bc4\u570d\uff0c\u5c07\u70ba\u66f4\u591a\u4e73\u817a\u764c\u548c\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u60a3\u8005\u5e36\u4f86\u81e8\u5e8a\u7372\u76ca\u3002\u6b64\u5916\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u5df2\u7372NMPA\u6388\u4e886\u9805\u7a81\u7834\u6027\u7642\u6cd5\u8a8d\u5b9a(BTD)\u3002 \u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u662f\u5168\u7403\u9996\u500b\u5728\u80ba\u764c\u9069\u61c9\u75c7\u7372\u6279\u4e0a\u5e02\u7684TROP2 ADC\u85e5\u7269\u3002\u76ee\u524d\uff0c\u79d1\u502b\u535a\u6cf0\u5df2\u5728\u4e2d\u570b\u958b\u5c559\u9805\u8a3b\u518a\u6027\u81e8\u5e8a\u7814\u7a76\u3002\u9ed8\u6c99\u6771\u5df2\u4f48\u5c4017\u9805\u6b63\u5728\u9032\u884c\u7684\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u4f5c\u70ba\u55ae\u85e5\u7642\u6cd5\u6216\u806f\u5408\u5e15\u535a\u5229\u73e0\u55ae\u6297\u6216\u5176\u4ed6\u6297\u764c\u85e5\u7269\u7528\u65bc\u591a\u7a2e\u985e\u578b\u764c\u75c7\u7684\u5168\u7403\u6027III\u671f\u81e8\u5e8a\u7814\u7a76(\u9019\u4e9b\u7814\u7a76\u7531\u9ed8\u6c99\u6771\u7533\u8fa6\u4e26\u4e3b\u5c0e)\u3002 \u95dc\u65bc\u79d1\u502b\u535a\u6cf0 \u56db\u5ddd\u79d1\u502b\u535a\u6cf0\u751f\u7269\u91ab\u85e5\u80a1\u4efd\u6709\u9650\u516c\u53f8(\u7c21\u7a31\u300c\u79d1\u502b\u535a\u6cf0\u300d\uff0c\u80a1\u7968\u4ee3\u78bc\uff1a6990.HK)\u662f\u79d1\u502b\u85e5\u696d\u63a7\u80a1\u5b50\u516c\u53f8\uff0c\u5c08\u6ce8\u4e8e\u5275\u65b0\u751f\u7269\u6280\u8853\u85e5\u7269\u53ca\u5c0f\u5206\u5b50\u85e5\u7269\u7684\u7814\u767c\u3001\u751f\u7522\u3001\u5546\u696d\u5316\u53ca\u570b\u969b\u5408\u4f5c\u3002\u516c\u53f8\u570d\u7e5e\u5168\u7403\u548c\u4e2d\u570b\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\uff0c\u91cd\u9ede\u4f48\u5c40\u816b\u7624\u3001\u81ea\u8eab\u514d\u75ab\u548c\u4ee3\u8b1d\u7b49\u91cd\u5927\u75be\u75c5\u9818\u57df\uff0c\u5efa\u8a2d\u570b\u969b\u5316\u85e5\u7269\u7814\u767c\u8207\u7522\u696d\u5316\u5e73\u81fa\uff0c\u81f4\u529b\u65bc\u6210\u70ba\u5728\u5275\u65b0\u85e5\u7269\u9818\u57df\u570b\u969b\u9818\u5148\u7684\u4f01\u696d\u3002\u516c\u53f8\u76ee\u524d\u64c1\u670930\u4f59\u500b\u91cd\u9ede\u5275\u65b0\u85e5\u9805\u76ee\uff0c\u5176\u4e2d4\u500b\u9805\u76ee8\u500b\u9069\u61c9\u75c7\u5df2\u7372\u6279\u4e0a\u5e02\uff0c1\u500b\u5c08\u6848\u8655\u65bcNDA\u968e\u6bb5\uff0c10\u9918\u500b\u5c08\u6848\u6b63\u8655\u65bc\u81e8\u5e8a\u968e\u6bb5\u3002\u516c\u53f8\u6210\u529f\u69cb\u5efa\u4e86\u4eab\u8b7d\u570b\u969b\u7684\u5c08\u6709ADC\u53ca\u65b0\u578b\u5076\u806f\u85e5\u7269\u5e73\u81faOptiDCTM\uff0c\u5df2\u67092\u500bADC\u9805\u76ee5\u500b\u9069\u61c9\u75c7\u7372\u6279\u4e0a\u5e02\uff0c\u591a\u500bADC\u6216\u65b0\u578b\u5076\u806f\u85e5\u7269\u7522\u54c1\u8655\u65bc\u81e8\u5e8a\u6216\u81e8\u5e8a\u524d\u7814\u7a76\u968e\u6bb5\u3002 \u53c3\u8003\u4f86\u6e90\uff1a Fang W, Li X, Wang Q, et al. Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutant advanced non-small-cell lung cancer: open label, randomised, multicentre trial. BMJ. 2025 Jun 5:389:e085680. doi: 10.1136\/bmj-2025-085680. Fang W, Wu L, Meng X, et al. Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR-Mutated Advanced NSCLC. NEJM. 2026 Jan 1;394(1):13-26. doi: 10.1056\/NEJMoa2512071. Epub 2025 Oct 19.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pingtungtimes.com.tw\/?p=419001\" \/>\n<meta property=\"og:locale\" content=\"zh_TW\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u7e3d\u751f\u5b58\u671f\u986f\u8457\u5ef6\u9577\uff1a\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT) OptiTROP-Lung03\u7814\u7a76OS\u6700\u7d42\u5206\u6790\u7d50\u679c\u4eae\u76f8 - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\" \/>\n<meta property=\"og:description\" content=\"\u6210\u90fd2026\u5e743\u670818\u65e5 \/\u7f8e\u901a\u793e\/ -- 2026\u5e74\u6b50\u6d32\u80ba\u764c\u5927\u6703(ELCC)\u5c07\u65bc\u7576\u5730\u6642\u95933\u670825\u65e5\u81f328\u65e5\u5728\u4e39\u9ea5\u54e5\u672c\u54c8\u6839\u8209\u884c\u3002\u672c\u6b21\u6703\u8b70\u4e0a\uff0c\u56db\u5ddd\u79d1\u502b\u535a\u6cf0\u751f\u7269\u91ab\u85e5\u80a1\u4efd\u6709\u9650\u516c\u53f8(\u300c\u79d1\u502b\u535a\u6cf0\u300d\u6216\u300c\u516c\u53f8\u300d\uff0c6990.HK)\u81ea\u4e3b\u7814\u767c\u7684TROP2 ADC\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297( sac-TMT\uff0c\u4ea6\u7a31SKB264\/MK-2870)(\u4f73\u6cf0\u840a\u00ae)\u95dc\u9375\u81e8\u5e8a\u7814\u7a76(OptiTROP-Lung03)\u7684OS\u6700\u7d42\u5206\u6790\u7d50\u679c\u6210\u529f\u5165\u9078\u7a81\u7834\u6027\u6458\u8981(LBA)(\u5831\u544a\u7de8\u865f\uff1aLBA4)\uff0c\u5c46\u6642\u5c07\u7531\u4e2d\u5c71\u5927\u5b78\u816b\u7624\u9632\u6cbb\u4e2d\u5fc3\u694a\u96f2\u9d6c\u6559\u6388\u5728\u5c0f\u578b\u53e3\u982d\u5831\u544a\u5c08\u5834\uff08Mini Oral Session\uff09\u5411\u5168\u7403\u5b78\u8005\u5f59\u5831\u5206\u4eab\uff0c\u6458\u8981\u5df2\u767c\u4f48\u65bcESMO Open\u671f\u520a\u3002 OptiTROP-Lung03\u7814\u7a76\u65e8\u5728\u8a55\u4f30\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u55ae\u4e00\u7642\u6cd5(5 mg\/kg\u6bcf2\u9031\u4e00\u6b21) \u5c0d\u6bd4\u591a\u897f\u4ed6\u8cfd\uff0c\u5728\u65e2\u5f80\u63a5\u53d7\u904eEGFR-TKI\u548c\u542b\u9251\u5316\u7642\u6cbb\u7642\u7684\u5c40\u90e8\u665a\u671f\u6216\u8f49\u79fb\u6027EGFR\u7a81\u8b8a\u975e\u5c0f\u7d30\u80de\u80ba\u764c(NSCLC)\u60a3\u8005\u4e2d\u7684\u6709\u6548\u6027\u548c\u5b89\u5168\u6027\u3002\u6b64\u524d\u57282025\u5e74ASCO\u5e74\u6703\u4e0a\u516c\u4f48\u7684\u7d50\u679c\u986f\u793a\uff0c\u5728137\u4f8b\u96a8\u6a5f\u5165\u7d44\u7684\u60a3\u8005\u4e2d\uff0c\u76f8\u8f03\u65bc\u591a\u897f\u4ed6\u8cfd\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u5728\u7121\u9032\u5c55\u751f\u5b58\u671f(PFS\uff09\u548c\u7e3d\u751f\u5b58\u671f(OS)\u65b9\u9762\u5177\u6709\u986f\u8457\u7d71\u8a08\u5b78\u610f\u7fa9\u548c\u81e8\u5e8a\u610f\u7fa9\u7684\u6539\u5584\u2014\u2014\u7d93BICR\u8a55\u4f30\u7684PFS\u98a8\u96aa\u6bd4(HR)\u70ba0.30(95% CI: 0.20-0.46, \u55ae\u5074p<0.001)\uff1bOS\u7684HR\u70ba0.49(95% CI: 0.27-0.88, \u55ae\u5074p=0.007)\u3002\u57fa\u65bc\u9019\u4e00\u7a4d\u6975\u7d50\u679c\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u7372\u570b\u5bb6\u85e5\u54c1\u76e3\u7763\u7ba1\u7406\u5c40(NMPA)\u6279\u51c6\u6b64\u9069\u61c9\u75c7\uff0c\u8a72\u9069\u61c9\u75c7\u5df2\u88ab\u7d0d\u5165\u570b\u5bb6\u91ab\u4fdd\u76ee\u9304\u3002 2026 ELCC\u6703\u8b70\u5c07\u516c\u4f48OptiTROP-Lung03\u7814\u7a76\u7684OS\u6700\u7d42\u5206\u6790\u7d50\u679c\u53ca\u66f4\u65b0\u7684PFS\u8cc7\u6599\u7b49(\u622a\u81f32025\u5e7412\u670811\u65e5\uff0c\u4e2d\u4f4d\u96a8\u8a2a\u6642\u9593\u70ba23.8\u500b\u6708)\uff0c\u4e3b\u8981\u5167\u5bb9\u5982\u4e0b\uff1a \u591a\u897f\u4ed6\u8cfd\u6cbb\u7642\u5c0d\u7167\u7d44\uff0c\u670941.3%\u7684\u60a3\u8005\u5728\u75be\u75c5\u9032\u5c55\u5f8c\u9078\u64c7\u63a5\u53d7\u4e86\u5f8c\u7e8c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u6cbb\u7642\u3002 \u8003\u616e\u5c0d\u7167\u7d44\u4ea4\u53c9\u6cbb\u7642\u5c0dOS\u5f71\u97ff\uff0c\u63a1\u7528\u9810\u8a2d\u7684\u79e9\u4fdd\u6301\u7d50\u69cb\u5931\u6548\u6642\u9593(RPSFT)\u6a21\u578b\u9032\u884c\u6821\u6b63\u5206\u6790\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u7d44\u8207\u591a\u897f\u4ed6\u8cfd\u7d44\u4e2d\u4f4dOS\u5206\u5225\u70ba20.0\u500b\u6708 vs 11.2\u500b\u6708(HR 0.45, 95% CI : 0.28-0.73)\uff0c18\u500b\u6708OS\u7387\u5206\u5225\u70ba54.7% vs 9.1%\uff1b \u82e5\u5c0d\u7167\u7d44OS\u4e0d\u7d93\u5f8c\u7e8csac-TMT\u6cbb\u7642\u6821\u6b63\uff0c\u5169\u7d44\u7684\u4e2d\u4f4dOS\u5247\u70ba20.0\u500b\u6708 vs 13.5\u500b\u6708(HR 0.63, 95% CI: 0.40-0.98)\uff1b \u7814\u7a76\u8005(INV)\u8a55\u4f30\u7684\u4e2d\u4f4dPFS\u70ba7.9\u500b\u6708 vs 2.8\u500b\u6708(HR 0.23, 95% CI: 0.15-0.35)\u3002 \u503c\u5f97\u4e00\u63d0\u7684\u662f\uff0c\u57fa\u65bc\u53e6\u5916\u4e00\u9805OptiTROP-Lung04\u7814\u7a76\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT) \u5df2\u7372NMPA\u6279\u51c6\u7528\u65bc\u7d93EGFR-TKI\u6cbb\u7642\u5f8c\u9032\u5c55\u7684\u665a\u671f\u6216\u8f49\u79fb\u6027EGFR\u7a81\u8b8aNSCLC, \u76f8\u95dc\u7d50\u679c\u5df2\u540c\u6b65\u767c\u8868\u65bc\u300a\u65b0\u82f1\u683c\u862d\u91ab\u5b78\u96dc\u8a8c\u300b\u3002\u800c\u6b64\u6b21\u5728\u7d93EGFR-TKI\u548c\u542b\u9251\u5316\u7642\u6cbb\u7642\u5f8c\u9032\u5c55\u7684EGFRm NSCLC\u4eba\u7fa4\u4e2d\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297\u53d6\u5f97\u4e86\u5177\u6709\u986f\u8457\u7d71\u8a08\u5b78\u610f\u7fa9\u548c\u81e8\u5e8a\u610f\u7fa9\u7684\u751f\u5b58\u7372\u76ca\uff0c\u4e2d\u4f4dOS\u9577\u905420\u500b\u6708\u3002\u5169\u9805\u95dc\u9375\u8a3b\u518a\u7814\u7a76\u7684\u76f8\u7e7c\u9a57\u8b49\uff0c\u9032\u4e00\u6b65\u78ba\u7acb\u4e86\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u5728\u7d93\u6cbbEGFR\u7a81\u8b8aNSCLC\u6cbb\u7642\u9818\u57df\u7684\u9818\u5148\u5730\u4f4d\uff0c\u70ba\u665a\u671f\u80ba\u764c\u60a3\u8005\u63d0\u4f9b\u4e86\u66f4\u5177\u78ba\u5b9a\u6027\u8207\u9577\u671f\u751f\u5b58\u7372\u76ca\u7684\u6cbb\u7642\u9078\u64c7\u3002 \u95dc\u65bc\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)(\u4f73\u6cf0\u840a\u00ae) \u4f5c\u70ba\u516c\u53f8\u7684\u6838\u5fc3\u7522\u54c1\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u662f\u4e00\u6b3e\u516c\u53f8\u64c1\u6709\u81ea\u4e3b\u667a\u6167\u8ca1\u7522\u6b0a\u7684\u65b0\u578bTROP2 ADC\uff0c\u91dd\u5c0dNSCLC\u3001\u4e73\u817a\u764c(BC)\u3001\u80c3\u764c(GC)\u3001\u5a66\u79d1\u816b\u7624\u7b49\u665a\u671f\u5be6\u9ad4\u7624\u3002\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u63a1\u7528\u65b0\u578b\u9023\u63a5\u5b50\u9032\u884c\u958b\u767c\uff0c\u5176\u901a\u904e\u5076\u806f\u4e00\u7a2e\u8c9d\u6d1b\u66ff\u5eb7\u884d\u751f\u7684\u62d3\u64b2\u7570\u69cb\u9176I\u6291\u5236\u5291\u4f5c\u70ba\u6709\u6548\u8f09\u8377\uff0c\u85e5\u7269\u6297\u9ad4\u6bd4(DAR)\u9054\u52307.4\u3002\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u901a\u904e\u91cd\u7d44\u6297TROP2\u4eba\u6e90\u5316\u55ae\u514b\u9686\u6297\u9ad4\u7279\u7570\u6027\u8b58\u5225\u816b\u7624\u7d30\u80de\u8868\u9762\u7684TROP2\uff0c\u5176\u5f8c\u88ab\u816b\u7624\u7d30\u80de\u5167\u541e\u4f75\u65bc\u7d30\u80de\u5167\u91cb\u653e\u6709\u6548\u8f09\u8377KL610023\u3002KL610023\u4f5c\u70ba\u62d3\u64b2\u7570\u69cb\u9176I\u6291\u5236\u5291\uff0c\u53ef\u8a98\u5c0e\u816b\u7624\u7d30\u80deDNA\u640d\u50b7\uff0c\u9032\u800c\u5c0e\u81f4\u7d30\u80de\u9031\u671f\u963b\u6eef\u53ca\u7d30\u80de\u51cb\u4ea1\u3002\u6b64\u5916\uff0c\u5176\u4ea6\u65bc\u816b\u7624\u5fae\u74b0\u5883\u4e2d\u91cb\u653eKL610023\u3002\u9452\u65bcKL610023\u5177\u6709\u7d30\u80de\u819c\u6ef2\u900f\u6027\uff0c\u5176\u53ef\u5be6\u73fe\u65c1\u89c0\u8005\u6548\u61c9\uff0c\u5373\u6bba\u6b7b\u9130\u8fd1\u7684\u816b\u7624\u7d30\u80de\u3002 \u65bc2022\u5e745\u6708\uff0c\u516c\u53f8\u6388\u4e88\u9ed8\u6c99\u6771(\u7f8e\u570b\u65b0\u6fa4\u897f\u5dde\u7f85\u5a01\u5e02\u9ed8\u514b\u516c\u53f8\u7684\u5546\u865f)\u5728\u5927\u4e2d\u83ef\u5340(\u5305\u62ec\u4e2d\u570b\u5167\u5730\u3001\u9999\u6e2f\u3001\u6fb3\u9580\u53ca\u81fa\u7063)\u4ee5\u5916\u7684\u6240\u6709\u5730\u5340\u958b\u767c\u3001\u4f7f\u7528\u3001\u88fd\u9020\u53ca\u5546\u696d\u5316\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u7684\u7368\u5bb6\u6b0a\u5229\u3002 \u622a\u81f3\u76ee\u524d\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u76844\u9805\u9069\u61c9\u75c7\u5df2\u65bc\u4e2d\u570b\u7372\u6279\u4e0a\u5e02\uff0c\u5206\u5225\u7528\u65bc\uff1a\u7d93EGFR-TKI\u548c\u542b\u9251\u5316\u7642\u6cbb\u7642\u5f8c\u9032\u5c55\u7684EGFR\u57fa\u56e0\u7a81\u8b8a\u967d\u6027\u7684\u5c40\u90e8\u665a\u671f\u6216\u8f49\u79fb\u6027\u975e\u9c57\u72c0NSCLC\uff1b\u65e2\u5f80\u81f3\u5c11\u63a5\u53d7\u904e2\u7a2e\u7cfb\u7d71\u6cbb\u7642\uff08\u5176\u4e2d\u81f3\u5c111\u7a2e\u6cbb\u7642\u91dd\u5c0d\u665a\u671f\u6216\u8f49\u79fb\u6027\u968e\u6bb5\uff09\u7684\u4e0d\u53ef\u5207\u9664\u7684\u5c40\u90e8\u665a\u671f\u6216\u8f49\u79fb\u6027TNBC\uff1b\u7d93EGFR-TKI\u6cbb\u7642\u5f8c\u9032\u5c55\u7684EGFR\u57fa\u56e0\u7a81\u8b8a\u967d\u6027\u7684\u5c40\u90e8\u665a\u671f\u6216\u8f49\u79fb\u6027\u975e\u9c57\u72c0NSCLC\uff1b\u65e2\u5f80\u63a5\u53d7\u904e\u5167\u5206\u6ccc\u6cbb\u7642\u4e14\u5728\u665a\u671f\u75be\u75c5\u968e\u6bb5\u63a5\u53d7\u904e\u81f3\u5c11\u4e00\u7dda\u5316\u7642\u7684\u4e0d\u53ef\u5207\u9664\u6216\u8f49\u79fb\u6027\u7684HR+\/HER2- (IHC 0\u3001IHC 1+\u6216IHC 2+\/ISH-) BC\uff1b\u5176\u4e2d\u524d2\u9805\u9069\u61c9\u75c7\u5df2\u7d93\u88ab\u7d0d\u5165\u91ab\u4fdd\u7bc4\u570d\uff0c\u5c07\u70ba\u66f4\u591a\u4e73\u817a\u764c\u548c\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u60a3\u8005\u5e36\u4f86\u81e8\u5e8a\u7372\u76ca\u3002\u6b64\u5916\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u5df2\u7372NMPA\u6388\u4e886\u9805\u7a81\u7834\u6027\u7642\u6cd5\u8a8d\u5b9a(BTD)\u3002 \u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u662f\u5168\u7403\u9996\u500b\u5728\u80ba\u764c\u9069\u61c9\u75c7\u7372\u6279\u4e0a\u5e02\u7684TROP2 ADC\u85e5\u7269\u3002\u76ee\u524d\uff0c\u79d1\u502b\u535a\u6cf0\u5df2\u5728\u4e2d\u570b\u958b\u5c559\u9805\u8a3b\u518a\u6027\u81e8\u5e8a\u7814\u7a76\u3002\u9ed8\u6c99\u6771\u5df2\u4f48\u5c4017\u9805\u6b63\u5728\u9032\u884c\u7684\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u4f5c\u70ba\u55ae\u85e5\u7642\u6cd5\u6216\u806f\u5408\u5e15\u535a\u5229\u73e0\u55ae\u6297\u6216\u5176\u4ed6\u6297\u764c\u85e5\u7269\u7528\u65bc\u591a\u7a2e\u985e\u578b\u764c\u75c7\u7684\u5168\u7403\u6027III\u671f\u81e8\u5e8a\u7814\u7a76(\u9019\u4e9b\u7814\u7a76\u7531\u9ed8\u6c99\u6771\u7533\u8fa6\u4e26\u4e3b\u5c0e)\u3002 \u95dc\u65bc\u79d1\u502b\u535a\u6cf0 \u56db\u5ddd\u79d1\u502b\u535a\u6cf0\u751f\u7269\u91ab\u85e5\u80a1\u4efd\u6709\u9650\u516c\u53f8(\u7c21\u7a31\u300c\u79d1\u502b\u535a\u6cf0\u300d\uff0c\u80a1\u7968\u4ee3\u78bc\uff1a6990.HK)\u662f\u79d1\u502b\u85e5\u696d\u63a7\u80a1\u5b50\u516c\u53f8\uff0c\u5c08\u6ce8\u4e8e\u5275\u65b0\u751f\u7269\u6280\u8853\u85e5\u7269\u53ca\u5c0f\u5206\u5b50\u85e5\u7269\u7684\u7814\u767c\u3001\u751f\u7522\u3001\u5546\u696d\u5316\u53ca\u570b\u969b\u5408\u4f5c\u3002\u516c\u53f8\u570d\u7e5e\u5168\u7403\u548c\u4e2d\u570b\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\uff0c\u91cd\u9ede\u4f48\u5c40\u816b\u7624\u3001\u81ea\u8eab\u514d\u75ab\u548c\u4ee3\u8b1d\u7b49\u91cd\u5927\u75be\u75c5\u9818\u57df\uff0c\u5efa\u8a2d\u570b\u969b\u5316\u85e5\u7269\u7814\u767c\u8207\u7522\u696d\u5316\u5e73\u81fa\uff0c\u81f4\u529b\u65bc\u6210\u70ba\u5728\u5275\u65b0\u85e5\u7269\u9818\u57df\u570b\u969b\u9818\u5148\u7684\u4f01\u696d\u3002\u516c\u53f8\u76ee\u524d\u64c1\u670930\u4f59\u500b\u91cd\u9ede\u5275\u65b0\u85e5\u9805\u76ee\uff0c\u5176\u4e2d4\u500b\u9805\u76ee8\u500b\u9069\u61c9\u75c7\u5df2\u7372\u6279\u4e0a\u5e02\uff0c1\u500b\u5c08\u6848\u8655\u65bcNDA\u968e\u6bb5\uff0c10\u9918\u500b\u5c08\u6848\u6b63\u8655\u65bc\u81e8\u5e8a\u968e\u6bb5\u3002\u516c\u53f8\u6210\u529f\u69cb\u5efa\u4e86\u4eab\u8b7d\u570b\u969b\u7684\u5c08\u6709ADC\u53ca\u65b0\u578b\u5076\u806f\u85e5\u7269\u5e73\u81faOptiDCTM\uff0c\u5df2\u67092\u500bADC\u9805\u76ee5\u500b\u9069\u61c9\u75c7\u7372\u6279\u4e0a\u5e02\uff0c\u591a\u500bADC\u6216\u65b0\u578b\u5076\u806f\u85e5\u7269\u7522\u54c1\u8655\u65bc\u81e8\u5e8a\u6216\u81e8\u5e8a\u524d\u7814\u7a76\u968e\u6bb5\u3002 \u53c3\u8003\u4f86\u6e90\uff1a Fang W, Li X, Wang Q, et al. Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutant advanced non-small-cell lung cancer: open label, randomised, multicentre trial. BMJ. 2025 Jun 5:389:e085680. doi: 10.1136\/bmj-2025-085680. Fang W, Wu L, Meng X, et al. Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR-Mutated Advanced NSCLC. NEJM. 2026 Jan 1;394(1):13-26. doi: 10.1056\/NEJMoa2512071. Epub 2025 Oct 19.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pingtungtimes.com.tw\/?p=419001\" \/>\n<meta property=\"og:site_name\" content=\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/pingtungnews\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-18T15:22:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3000\" \/>\n\t<meta property=\"og:image:height\" content=\"1990\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u7f8e\u901a\u793e\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u4f5c\u8005:\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u7f8e\u901a\u793e\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u9810\u4f30\u95b1\u8b80\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 \u5206\u9418\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=419001#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=419001\"},\"author\":{\"name\":\"\u7f8e\u901a\u793e\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/person\\\/683b937f29ec1537972f6c41e22a2cf3\"},\"headline\":\"\u7e3d\u751f\u5b58\u671f\u986f\u8457\u5ef6\u9577\uff1a\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT) OptiTROP-Lung03\u7814\u7a76OS\u6700\u7d42\u5206\u6790\u7d50\u679c\u4eae\u76f8\",\"datePublished\":\"2026-03-18T15:22:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=419001\"},\"wordCount\":191,\"publisher\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=419001#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1-17.jpg\",\"articleSection\":[\"\u7f8e\u901a\u793e\"],\"inLanguage\":\"zh-TW\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=419001\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=419001\",\"name\":\"\u7e3d\u751f\u5b58\u671f\u986f\u8457\u5ef6\u9577\uff1a\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT) OptiTROP-Lung03\u7814\u7a76OS\u6700\u7d42\u5206\u6790\u7d50\u679c\u4eae\u76f8 - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=419001#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=419001#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1-17.jpg\",\"datePublished\":\"2026-03-18T15:22:00+00:00\",\"description\":\"\u6210\u90fd2026\u5e743\u670818\u65e5 \\\/\u7f8e\u901a\u793e\\\/ -- 2026\u5e74\u6b50\u6d32\u80ba\u764c\u5927\u6703(ELCC)\u5c07\u65bc\u7576\u5730\u6642\u95933\u670825\u65e5\u81f328\u65e5\u5728\u4e39\u9ea5\u54e5\u672c\u54c8\u6839\u8209\u884c\u3002\u672c\u6b21\u6703\u8b70\u4e0a\uff0c\u56db\u5ddd\u79d1\u502b\u535a\u6cf0\u751f\u7269\u91ab\u85e5\u80a1\u4efd\u6709\u9650\u516c\u53f8(\u300c\u79d1\u502b\u535a\u6cf0\u300d\u6216\u300c\u516c\u53f8\u300d\uff0c6990.HK)\u81ea\u4e3b\u7814\u767c\u7684TROP2 ADC\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297( sac-TMT\uff0c\u4ea6\u7a31SKB264\\\/MK-2870)(\u4f73\u6cf0\u840a\u00ae)\u95dc\u9375\u81e8\u5e8a\u7814\u7a76(OptiTROP-Lung03)\u7684OS\u6700\u7d42\u5206\u6790\u7d50\u679c\u6210\u529f\u5165\u9078\u7a81\u7834\u6027\u6458\u8981(LBA)(\u5831\u544a\u7de8\u865f\uff1aLBA4)\uff0c\u5c46\u6642\u5c07\u7531\u4e2d\u5c71\u5927\u5b78\u816b\u7624\u9632\u6cbb\u4e2d\u5fc3\u694a\u96f2\u9d6c\u6559\u6388\u5728\u5c0f\u578b\u53e3\u982d\u5831\u544a\u5c08\u5834\uff08Mini Oral Session\uff09\u5411\u5168\u7403\u5b78\u8005\u5f59\u5831\u5206\u4eab\uff0c\u6458\u8981\u5df2\u767c\u4f48\u65bcESMO Open\u671f\u520a\u3002 OptiTROP-Lung03\u7814\u7a76\u65e8\u5728\u8a55\u4f30\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u55ae\u4e00\u7642\u6cd5(5 mg\\\/kg\u6bcf2\u9031\u4e00\u6b21) \u5c0d\u6bd4\u591a\u897f\u4ed6\u8cfd\uff0c\u5728\u65e2\u5f80\u63a5\u53d7\u904eEGFR-TKI\u548c\u542b\u9251\u5316\u7642\u6cbb\u7642\u7684\u5c40\u90e8\u665a\u671f\u6216\u8f49\u79fb\u6027EGFR\u7a81\u8b8a\u975e\u5c0f\u7d30\u80de\u80ba\u764c(NSCLC)\u60a3\u8005\u4e2d\u7684\u6709\u6548\u6027\u548c\u5b89\u5168\u6027\u3002\u6b64\u524d\u57282025\u5e74ASCO\u5e74\u6703\u4e0a\u516c\u4f48\u7684\u7d50\u679c\u986f\u793a\uff0c\u5728137\u4f8b\u96a8\u6a5f\u5165\u7d44\u7684\u60a3\u8005\u4e2d\uff0c\u76f8\u8f03\u65bc\u591a\u897f\u4ed6\u8cfd\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u5728\u7121\u9032\u5c55\u751f\u5b58\u671f(PFS\uff09\u548c\u7e3d\u751f\u5b58\u671f(OS)\u65b9\u9762\u5177\u6709\u986f\u8457\u7d71\u8a08\u5b78\u610f\u7fa9\u548c\u81e8\u5e8a\u610f\u7fa9\u7684\u6539\u5584\u2014\u2014\u7d93BICR\u8a55\u4f30\u7684PFS\u98a8\u96aa\u6bd4(HR)\u70ba0.30(95% CI: 0.20-0.46, \u55ae\u5074p<0.001)\uff1bOS\u7684HR\u70ba0.49(95% CI: 0.27-0.88, \u55ae\u5074p=0.007)\u3002\u57fa\u65bc\u9019\u4e00\u7a4d\u6975\u7d50\u679c\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u7372\u570b\u5bb6\u85e5\u54c1\u76e3\u7763\u7ba1\u7406\u5c40(NMPA)\u6279\u51c6\u6b64\u9069\u61c9\u75c7\uff0c\u8a72\u9069\u61c9\u75c7\u5df2\u88ab\u7d0d\u5165\u570b\u5bb6\u91ab\u4fdd\u76ee\u9304\u3002 2026 ELCC\u6703\u8b70\u5c07\u516c\u4f48OptiTROP-Lung03\u7814\u7a76\u7684OS\u6700\u7d42\u5206\u6790\u7d50\u679c\u53ca\u66f4\u65b0\u7684PFS\u8cc7\u6599\u7b49(\u622a\u81f32025\u5e7412\u670811\u65e5\uff0c\u4e2d\u4f4d\u96a8\u8a2a\u6642\u9593\u70ba23.8\u500b\u6708)\uff0c\u4e3b\u8981\u5167\u5bb9\u5982\u4e0b\uff1a \u591a\u897f\u4ed6\u8cfd\u6cbb\u7642\u5c0d\u7167\u7d44\uff0c\u670941.3%\u7684\u60a3\u8005\u5728\u75be\u75c5\u9032\u5c55\u5f8c\u9078\u64c7\u63a5\u53d7\u4e86\u5f8c\u7e8c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u6cbb\u7642\u3002 \u8003\u616e\u5c0d\u7167\u7d44\u4ea4\u53c9\u6cbb\u7642\u5c0dOS\u5f71\u97ff\uff0c\u63a1\u7528\u9810\u8a2d\u7684\u79e9\u4fdd\u6301\u7d50\u69cb\u5931\u6548\u6642\u9593(RPSFT)\u6a21\u578b\u9032\u884c\u6821\u6b63\u5206\u6790\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u7d44\u8207\u591a\u897f\u4ed6\u8cfd\u7d44\u4e2d\u4f4dOS\u5206\u5225\u70ba20.0\u500b\u6708 vs 11.2\u500b\u6708(HR 0.45, 95% CI : 0.28-0.73)\uff0c18\u500b\u6708OS\u7387\u5206\u5225\u70ba54.7% vs 9.1%\uff1b \u82e5\u5c0d\u7167\u7d44OS\u4e0d\u7d93\u5f8c\u7e8csac-TMT\u6cbb\u7642\u6821\u6b63\uff0c\u5169\u7d44\u7684\u4e2d\u4f4dOS\u5247\u70ba20.0\u500b\u6708 vs 13.5\u500b\u6708(HR 0.63, 95% CI: 0.40-0.98)\uff1b \u7814\u7a76\u8005(INV)\u8a55\u4f30\u7684\u4e2d\u4f4dPFS\u70ba7.9\u500b\u6708 vs 2.8\u500b\u6708(HR 0.23, 95% CI: 0.15-0.35)\u3002 \u503c\u5f97\u4e00\u63d0\u7684\u662f\uff0c\u57fa\u65bc\u53e6\u5916\u4e00\u9805OptiTROP-Lung04\u7814\u7a76\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT) \u5df2\u7372NMPA\u6279\u51c6\u7528\u65bc\u7d93EGFR-TKI\u6cbb\u7642\u5f8c\u9032\u5c55\u7684\u665a\u671f\u6216\u8f49\u79fb\u6027EGFR\u7a81\u8b8aNSCLC, \u76f8\u95dc\u7d50\u679c\u5df2\u540c\u6b65\u767c\u8868\u65bc\u300a\u65b0\u82f1\u683c\u862d\u91ab\u5b78\u96dc\u8a8c\u300b\u3002\u800c\u6b64\u6b21\u5728\u7d93EGFR-TKI\u548c\u542b\u9251\u5316\u7642\u6cbb\u7642\u5f8c\u9032\u5c55\u7684EGFRm NSCLC\u4eba\u7fa4\u4e2d\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297\u53d6\u5f97\u4e86\u5177\u6709\u986f\u8457\u7d71\u8a08\u5b78\u610f\u7fa9\u548c\u81e8\u5e8a\u610f\u7fa9\u7684\u751f\u5b58\u7372\u76ca\uff0c\u4e2d\u4f4dOS\u9577\u905420\u500b\u6708\u3002\u5169\u9805\u95dc\u9375\u8a3b\u518a\u7814\u7a76\u7684\u76f8\u7e7c\u9a57\u8b49\uff0c\u9032\u4e00\u6b65\u78ba\u7acb\u4e86\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u5728\u7d93\u6cbbEGFR\u7a81\u8b8aNSCLC\u6cbb\u7642\u9818\u57df\u7684\u9818\u5148\u5730\u4f4d\uff0c\u70ba\u665a\u671f\u80ba\u764c\u60a3\u8005\u63d0\u4f9b\u4e86\u66f4\u5177\u78ba\u5b9a\u6027\u8207\u9577\u671f\u751f\u5b58\u7372\u76ca\u7684\u6cbb\u7642\u9078\u64c7\u3002 \u95dc\u65bc\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)(\u4f73\u6cf0\u840a\u00ae) \u4f5c\u70ba\u516c\u53f8\u7684\u6838\u5fc3\u7522\u54c1\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u662f\u4e00\u6b3e\u516c\u53f8\u64c1\u6709\u81ea\u4e3b\u667a\u6167\u8ca1\u7522\u6b0a\u7684\u65b0\u578bTROP2 ADC\uff0c\u91dd\u5c0dNSCLC\u3001\u4e73\u817a\u764c(BC)\u3001\u80c3\u764c(GC)\u3001\u5a66\u79d1\u816b\u7624\u7b49\u665a\u671f\u5be6\u9ad4\u7624\u3002\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u63a1\u7528\u65b0\u578b\u9023\u63a5\u5b50\u9032\u884c\u958b\u767c\uff0c\u5176\u901a\u904e\u5076\u806f\u4e00\u7a2e\u8c9d\u6d1b\u66ff\u5eb7\u884d\u751f\u7684\u62d3\u64b2\u7570\u69cb\u9176I\u6291\u5236\u5291\u4f5c\u70ba\u6709\u6548\u8f09\u8377\uff0c\u85e5\u7269\u6297\u9ad4\u6bd4(DAR)\u9054\u52307.4\u3002\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u901a\u904e\u91cd\u7d44\u6297TROP2\u4eba\u6e90\u5316\u55ae\u514b\u9686\u6297\u9ad4\u7279\u7570\u6027\u8b58\u5225\u816b\u7624\u7d30\u80de\u8868\u9762\u7684TROP2\uff0c\u5176\u5f8c\u88ab\u816b\u7624\u7d30\u80de\u5167\u541e\u4f75\u65bc\u7d30\u80de\u5167\u91cb\u653e\u6709\u6548\u8f09\u8377KL610023\u3002KL610023\u4f5c\u70ba\u62d3\u64b2\u7570\u69cb\u9176I\u6291\u5236\u5291\uff0c\u53ef\u8a98\u5c0e\u816b\u7624\u7d30\u80deDNA\u640d\u50b7\uff0c\u9032\u800c\u5c0e\u81f4\u7d30\u80de\u9031\u671f\u963b\u6eef\u53ca\u7d30\u80de\u51cb\u4ea1\u3002\u6b64\u5916\uff0c\u5176\u4ea6\u65bc\u816b\u7624\u5fae\u74b0\u5883\u4e2d\u91cb\u653eKL610023\u3002\u9452\u65bcKL610023\u5177\u6709\u7d30\u80de\u819c\u6ef2\u900f\u6027\uff0c\u5176\u53ef\u5be6\u73fe\u65c1\u89c0\u8005\u6548\u61c9\uff0c\u5373\u6bba\u6b7b\u9130\u8fd1\u7684\u816b\u7624\u7d30\u80de\u3002 \u65bc2022\u5e745\u6708\uff0c\u516c\u53f8\u6388\u4e88\u9ed8\u6c99\u6771(\u7f8e\u570b\u65b0\u6fa4\u897f\u5dde\u7f85\u5a01\u5e02\u9ed8\u514b\u516c\u53f8\u7684\u5546\u865f)\u5728\u5927\u4e2d\u83ef\u5340(\u5305\u62ec\u4e2d\u570b\u5167\u5730\u3001\u9999\u6e2f\u3001\u6fb3\u9580\u53ca\u81fa\u7063)\u4ee5\u5916\u7684\u6240\u6709\u5730\u5340\u958b\u767c\u3001\u4f7f\u7528\u3001\u88fd\u9020\u53ca\u5546\u696d\u5316\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u7684\u7368\u5bb6\u6b0a\u5229\u3002 \u622a\u81f3\u76ee\u524d\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u76844\u9805\u9069\u61c9\u75c7\u5df2\u65bc\u4e2d\u570b\u7372\u6279\u4e0a\u5e02\uff0c\u5206\u5225\u7528\u65bc\uff1a\u7d93EGFR-TKI\u548c\u542b\u9251\u5316\u7642\u6cbb\u7642\u5f8c\u9032\u5c55\u7684EGFR\u57fa\u56e0\u7a81\u8b8a\u967d\u6027\u7684\u5c40\u90e8\u665a\u671f\u6216\u8f49\u79fb\u6027\u975e\u9c57\u72c0NSCLC\uff1b\u65e2\u5f80\u81f3\u5c11\u63a5\u53d7\u904e2\u7a2e\u7cfb\u7d71\u6cbb\u7642\uff08\u5176\u4e2d\u81f3\u5c111\u7a2e\u6cbb\u7642\u91dd\u5c0d\u665a\u671f\u6216\u8f49\u79fb\u6027\u968e\u6bb5\uff09\u7684\u4e0d\u53ef\u5207\u9664\u7684\u5c40\u90e8\u665a\u671f\u6216\u8f49\u79fb\u6027TNBC\uff1b\u7d93EGFR-TKI\u6cbb\u7642\u5f8c\u9032\u5c55\u7684EGFR\u57fa\u56e0\u7a81\u8b8a\u967d\u6027\u7684\u5c40\u90e8\u665a\u671f\u6216\u8f49\u79fb\u6027\u975e\u9c57\u72c0NSCLC\uff1b\u65e2\u5f80\u63a5\u53d7\u904e\u5167\u5206\u6ccc\u6cbb\u7642\u4e14\u5728\u665a\u671f\u75be\u75c5\u968e\u6bb5\u63a5\u53d7\u904e\u81f3\u5c11\u4e00\u7dda\u5316\u7642\u7684\u4e0d\u53ef\u5207\u9664\u6216\u8f49\u79fb\u6027\u7684HR+\\\/HER2- (IHC 0\u3001IHC 1+\u6216IHC 2+\\\/ISH-) BC\uff1b\u5176\u4e2d\u524d2\u9805\u9069\u61c9\u75c7\u5df2\u7d93\u88ab\u7d0d\u5165\u91ab\u4fdd\u7bc4\u570d\uff0c\u5c07\u70ba\u66f4\u591a\u4e73\u817a\u764c\u548c\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u60a3\u8005\u5e36\u4f86\u81e8\u5e8a\u7372\u76ca\u3002\u6b64\u5916\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u5df2\u7372NMPA\u6388\u4e886\u9805\u7a81\u7834\u6027\u7642\u6cd5\u8a8d\u5b9a(BTD)\u3002 \u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u662f\u5168\u7403\u9996\u500b\u5728\u80ba\u764c\u9069\u61c9\u75c7\u7372\u6279\u4e0a\u5e02\u7684TROP2 ADC\u85e5\u7269\u3002\u76ee\u524d\uff0c\u79d1\u502b\u535a\u6cf0\u5df2\u5728\u4e2d\u570b\u958b\u5c559\u9805\u8a3b\u518a\u6027\u81e8\u5e8a\u7814\u7a76\u3002\u9ed8\u6c99\u6771\u5df2\u4f48\u5c4017\u9805\u6b63\u5728\u9032\u884c\u7684\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u4f5c\u70ba\u55ae\u85e5\u7642\u6cd5\u6216\u806f\u5408\u5e15\u535a\u5229\u73e0\u55ae\u6297\u6216\u5176\u4ed6\u6297\u764c\u85e5\u7269\u7528\u65bc\u591a\u7a2e\u985e\u578b\u764c\u75c7\u7684\u5168\u7403\u6027III\u671f\u81e8\u5e8a\u7814\u7a76(\u9019\u4e9b\u7814\u7a76\u7531\u9ed8\u6c99\u6771\u7533\u8fa6\u4e26\u4e3b\u5c0e)\u3002 \u95dc\u65bc\u79d1\u502b\u535a\u6cf0 \u56db\u5ddd\u79d1\u502b\u535a\u6cf0\u751f\u7269\u91ab\u85e5\u80a1\u4efd\u6709\u9650\u516c\u53f8(\u7c21\u7a31\u300c\u79d1\u502b\u535a\u6cf0\u300d\uff0c\u80a1\u7968\u4ee3\u78bc\uff1a6990.HK)\u662f\u79d1\u502b\u85e5\u696d\u63a7\u80a1\u5b50\u516c\u53f8\uff0c\u5c08\u6ce8\u4e8e\u5275\u65b0\u751f\u7269\u6280\u8853\u85e5\u7269\u53ca\u5c0f\u5206\u5b50\u85e5\u7269\u7684\u7814\u767c\u3001\u751f\u7522\u3001\u5546\u696d\u5316\u53ca\u570b\u969b\u5408\u4f5c\u3002\u516c\u53f8\u570d\u7e5e\u5168\u7403\u548c\u4e2d\u570b\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\uff0c\u91cd\u9ede\u4f48\u5c40\u816b\u7624\u3001\u81ea\u8eab\u514d\u75ab\u548c\u4ee3\u8b1d\u7b49\u91cd\u5927\u75be\u75c5\u9818\u57df\uff0c\u5efa\u8a2d\u570b\u969b\u5316\u85e5\u7269\u7814\u767c\u8207\u7522\u696d\u5316\u5e73\u81fa\uff0c\u81f4\u529b\u65bc\u6210\u70ba\u5728\u5275\u65b0\u85e5\u7269\u9818\u57df\u570b\u969b\u9818\u5148\u7684\u4f01\u696d\u3002\u516c\u53f8\u76ee\u524d\u64c1\u670930\u4f59\u500b\u91cd\u9ede\u5275\u65b0\u85e5\u9805\u76ee\uff0c\u5176\u4e2d4\u500b\u9805\u76ee8\u500b\u9069\u61c9\u75c7\u5df2\u7372\u6279\u4e0a\u5e02\uff0c1\u500b\u5c08\u6848\u8655\u65bcNDA\u968e\u6bb5\uff0c10\u9918\u500b\u5c08\u6848\u6b63\u8655\u65bc\u81e8\u5e8a\u968e\u6bb5\u3002\u516c\u53f8\u6210\u529f\u69cb\u5efa\u4e86\u4eab\u8b7d\u570b\u969b\u7684\u5c08\u6709ADC\u53ca\u65b0\u578b\u5076\u806f\u85e5\u7269\u5e73\u81faOptiDCTM\uff0c\u5df2\u67092\u500bADC\u9805\u76ee5\u500b\u9069\u61c9\u75c7\u7372\u6279\u4e0a\u5e02\uff0c\u591a\u500bADC\u6216\u65b0\u578b\u5076\u806f\u85e5\u7269\u7522\u54c1\u8655\u65bc\u81e8\u5e8a\u6216\u81e8\u5e8a\u524d\u7814\u7a76\u968e\u6bb5\u3002 \u53c3\u8003\u4f86\u6e90\uff1a Fang W, Li X, Wang Q, et al. Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutant advanced non-small-cell lung cancer: open label, randomised, multicentre trial. BMJ. 2025 Jun 5:389:e085680. doi: 10.1136\\\/bmj-2025-085680. Fang W, Wu L, Meng X, et al. Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR-Mutated Advanced NSCLC. NEJM. 2026 Jan 1;394(1):13-26. doi: 10.1056\\\/NEJMoa2512071. Epub 2025 Oct 19.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=419001#breadcrumb\"},\"inLanguage\":\"zh-TW\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=419001\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-TW\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=419001#primaryimage\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1-17.jpg\",\"contentUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1-17.jpg\",\"width\":400,\"height\":91},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=419001#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"\u9996\u9801\",\"item\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u7e3d\u751f\u5b58\u671f\u986f\u8457\u5ef6\u9577\uff1a\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT) OptiTROP-Lung03\u7814\u7a76OS\u6700\u7d42\u5206\u6790\u7d50\u679c\u4eae\u76f8\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#website\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/\",\"name\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\",\"description\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831PingtungTimes\uff0c\u6700\u95dc\u5fc3\u5728\u5730\u7684\u5a92\u9ad4\",\"publisher\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-TW\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#organization\",\"name\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-TW\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo-150.png\",\"contentUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo-150.png\",\"width\":150,\"height\":150,\"caption\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\"},\"image\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/pingtungnews\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/person\\\/683b937f29ec1537972f6c41e22a2cf3\",\"name\":\"\u7f8e\u901a\u793e\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-TW\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g\",\"caption\":\"\u7f8e\u901a\u793e\"},\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?author=16\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u7e3d\u751f\u5b58\u671f\u986f\u8457\u5ef6\u9577\uff1a\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT) OptiTROP-Lung03\u7814\u7a76OS\u6700\u7d42\u5206\u6790\u7d50\u679c\u4eae\u76f8 - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","description":"\u6210\u90fd2026\u5e743\u670818\u65e5 \/\u7f8e\u901a\u793e\/ -- 2026\u5e74\u6b50\u6d32\u80ba\u764c\u5927\u6703(ELCC)\u5c07\u65bc\u7576\u5730\u6642\u95933\u670825\u65e5\u81f328\u65e5\u5728\u4e39\u9ea5\u54e5\u672c\u54c8\u6839\u8209\u884c\u3002\u672c\u6b21\u6703\u8b70\u4e0a\uff0c\u56db\u5ddd\u79d1\u502b\u535a\u6cf0\u751f\u7269\u91ab\u85e5\u80a1\u4efd\u6709\u9650\u516c\u53f8(\u300c\u79d1\u502b\u535a\u6cf0\u300d\u6216\u300c\u516c\u53f8\u300d\uff0c6990.HK)\u81ea\u4e3b\u7814\u767c\u7684TROP2 ADC\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297( sac-TMT\uff0c\u4ea6\u7a31SKB264\/MK-2870)(\u4f73\u6cf0\u840a\u00ae)\u95dc\u9375\u81e8\u5e8a\u7814\u7a76(OptiTROP-Lung03)\u7684OS\u6700\u7d42\u5206\u6790\u7d50\u679c\u6210\u529f\u5165\u9078\u7a81\u7834\u6027\u6458\u8981(LBA)(\u5831\u544a\u7de8\u865f\uff1aLBA4)\uff0c\u5c46\u6642\u5c07\u7531\u4e2d\u5c71\u5927\u5b78\u816b\u7624\u9632\u6cbb\u4e2d\u5fc3\u694a\u96f2\u9d6c\u6559\u6388\u5728\u5c0f\u578b\u53e3\u982d\u5831\u544a\u5c08\u5834\uff08Mini Oral Session\uff09\u5411\u5168\u7403\u5b78\u8005\u5f59\u5831\u5206\u4eab\uff0c\u6458\u8981\u5df2\u767c\u4f48\u65bcESMO Open\u671f\u520a\u3002 OptiTROP-Lung03\u7814\u7a76\u65e8\u5728\u8a55\u4f30\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u55ae\u4e00\u7642\u6cd5(5 mg\/kg\u6bcf2\u9031\u4e00\u6b21) \u5c0d\u6bd4\u591a\u897f\u4ed6\u8cfd\uff0c\u5728\u65e2\u5f80\u63a5\u53d7\u904eEGFR-TKI\u548c\u542b\u9251\u5316\u7642\u6cbb\u7642\u7684\u5c40\u90e8\u665a\u671f\u6216\u8f49\u79fb\u6027EGFR\u7a81\u8b8a\u975e\u5c0f\u7d30\u80de\u80ba\u764c(NSCLC)\u60a3\u8005\u4e2d\u7684\u6709\u6548\u6027\u548c\u5b89\u5168\u6027\u3002\u6b64\u524d\u57282025\u5e74ASCO\u5e74\u6703\u4e0a\u516c\u4f48\u7684\u7d50\u679c\u986f\u793a\uff0c\u5728137\u4f8b\u96a8\u6a5f\u5165\u7d44\u7684\u60a3\u8005\u4e2d\uff0c\u76f8\u8f03\u65bc\u591a\u897f\u4ed6\u8cfd\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u5728\u7121\u9032\u5c55\u751f\u5b58\u671f(PFS\uff09\u548c\u7e3d\u751f\u5b58\u671f(OS)\u65b9\u9762\u5177\u6709\u986f\u8457\u7d71\u8a08\u5b78\u610f\u7fa9\u548c\u81e8\u5e8a\u610f\u7fa9\u7684\u6539\u5584\u2014\u2014\u7d93BICR\u8a55\u4f30\u7684PFS\u98a8\u96aa\u6bd4(HR)\u70ba0.30(95% CI: 0.20-0.46, \u55ae\u5074p<0.001)\uff1bOS\u7684HR\u70ba0.49(95% CI: 0.27-0.88, \u55ae\u5074p=0.007)\u3002\u57fa\u65bc\u9019\u4e00\u7a4d\u6975\u7d50\u679c\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u7372\u570b\u5bb6\u85e5\u54c1\u76e3\u7763\u7ba1\u7406\u5c40(NMPA)\u6279\u51c6\u6b64\u9069\u61c9\u75c7\uff0c\u8a72\u9069\u61c9\u75c7\u5df2\u88ab\u7d0d\u5165\u570b\u5bb6\u91ab\u4fdd\u76ee\u9304\u3002 2026 ELCC\u6703\u8b70\u5c07\u516c\u4f48OptiTROP-Lung03\u7814\u7a76\u7684OS\u6700\u7d42\u5206\u6790\u7d50\u679c\u53ca\u66f4\u65b0\u7684PFS\u8cc7\u6599\u7b49(\u622a\u81f32025\u5e7412\u670811\u65e5\uff0c\u4e2d\u4f4d\u96a8\u8a2a\u6642\u9593\u70ba23.8\u500b\u6708)\uff0c\u4e3b\u8981\u5167\u5bb9\u5982\u4e0b\uff1a \u591a\u897f\u4ed6\u8cfd\u6cbb\u7642\u5c0d\u7167\u7d44\uff0c\u670941.3%\u7684\u60a3\u8005\u5728\u75be\u75c5\u9032\u5c55\u5f8c\u9078\u64c7\u63a5\u53d7\u4e86\u5f8c\u7e8c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u6cbb\u7642\u3002 \u8003\u616e\u5c0d\u7167\u7d44\u4ea4\u53c9\u6cbb\u7642\u5c0dOS\u5f71\u97ff\uff0c\u63a1\u7528\u9810\u8a2d\u7684\u79e9\u4fdd\u6301\u7d50\u69cb\u5931\u6548\u6642\u9593(RPSFT)\u6a21\u578b\u9032\u884c\u6821\u6b63\u5206\u6790\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u7d44\u8207\u591a\u897f\u4ed6\u8cfd\u7d44\u4e2d\u4f4dOS\u5206\u5225\u70ba20.0\u500b\u6708 vs 11.2\u500b\u6708(HR 0.45, 95% CI : 0.28-0.73)\uff0c18\u500b\u6708OS\u7387\u5206\u5225\u70ba54.7% vs 9.1%\uff1b \u82e5\u5c0d\u7167\u7d44OS\u4e0d\u7d93\u5f8c\u7e8csac-TMT\u6cbb\u7642\u6821\u6b63\uff0c\u5169\u7d44\u7684\u4e2d\u4f4dOS\u5247\u70ba20.0\u500b\u6708 vs 13.5\u500b\u6708(HR 0.63, 95% CI: 0.40-0.98)\uff1b \u7814\u7a76\u8005(INV)\u8a55\u4f30\u7684\u4e2d\u4f4dPFS\u70ba7.9\u500b\u6708 vs 2.8\u500b\u6708(HR 0.23, 95% CI: 0.15-0.35)\u3002 \u503c\u5f97\u4e00\u63d0\u7684\u662f\uff0c\u57fa\u65bc\u53e6\u5916\u4e00\u9805OptiTROP-Lung04\u7814\u7a76\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT) \u5df2\u7372NMPA\u6279\u51c6\u7528\u65bc\u7d93EGFR-TKI\u6cbb\u7642\u5f8c\u9032\u5c55\u7684\u665a\u671f\u6216\u8f49\u79fb\u6027EGFR\u7a81\u8b8aNSCLC, \u76f8\u95dc\u7d50\u679c\u5df2\u540c\u6b65\u767c\u8868\u65bc\u300a\u65b0\u82f1\u683c\u862d\u91ab\u5b78\u96dc\u8a8c\u300b\u3002\u800c\u6b64\u6b21\u5728\u7d93EGFR-TKI\u548c\u542b\u9251\u5316\u7642\u6cbb\u7642\u5f8c\u9032\u5c55\u7684EGFRm NSCLC\u4eba\u7fa4\u4e2d\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297\u53d6\u5f97\u4e86\u5177\u6709\u986f\u8457\u7d71\u8a08\u5b78\u610f\u7fa9\u548c\u81e8\u5e8a\u610f\u7fa9\u7684\u751f\u5b58\u7372\u76ca\uff0c\u4e2d\u4f4dOS\u9577\u905420\u500b\u6708\u3002\u5169\u9805\u95dc\u9375\u8a3b\u518a\u7814\u7a76\u7684\u76f8\u7e7c\u9a57\u8b49\uff0c\u9032\u4e00\u6b65\u78ba\u7acb\u4e86\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u5728\u7d93\u6cbbEGFR\u7a81\u8b8aNSCLC\u6cbb\u7642\u9818\u57df\u7684\u9818\u5148\u5730\u4f4d\uff0c\u70ba\u665a\u671f\u80ba\u764c\u60a3\u8005\u63d0\u4f9b\u4e86\u66f4\u5177\u78ba\u5b9a\u6027\u8207\u9577\u671f\u751f\u5b58\u7372\u76ca\u7684\u6cbb\u7642\u9078\u64c7\u3002 \u95dc\u65bc\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)(\u4f73\u6cf0\u840a\u00ae) \u4f5c\u70ba\u516c\u53f8\u7684\u6838\u5fc3\u7522\u54c1\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u662f\u4e00\u6b3e\u516c\u53f8\u64c1\u6709\u81ea\u4e3b\u667a\u6167\u8ca1\u7522\u6b0a\u7684\u65b0\u578bTROP2 ADC\uff0c\u91dd\u5c0dNSCLC\u3001\u4e73\u817a\u764c(BC)\u3001\u80c3\u764c(GC)\u3001\u5a66\u79d1\u816b\u7624\u7b49\u665a\u671f\u5be6\u9ad4\u7624\u3002\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u63a1\u7528\u65b0\u578b\u9023\u63a5\u5b50\u9032\u884c\u958b\u767c\uff0c\u5176\u901a\u904e\u5076\u806f\u4e00\u7a2e\u8c9d\u6d1b\u66ff\u5eb7\u884d\u751f\u7684\u62d3\u64b2\u7570\u69cb\u9176I\u6291\u5236\u5291\u4f5c\u70ba\u6709\u6548\u8f09\u8377\uff0c\u85e5\u7269\u6297\u9ad4\u6bd4(DAR)\u9054\u52307.4\u3002\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u901a\u904e\u91cd\u7d44\u6297TROP2\u4eba\u6e90\u5316\u55ae\u514b\u9686\u6297\u9ad4\u7279\u7570\u6027\u8b58\u5225\u816b\u7624\u7d30\u80de\u8868\u9762\u7684TROP2\uff0c\u5176\u5f8c\u88ab\u816b\u7624\u7d30\u80de\u5167\u541e\u4f75\u65bc\u7d30\u80de\u5167\u91cb\u653e\u6709\u6548\u8f09\u8377KL610023\u3002KL610023\u4f5c\u70ba\u62d3\u64b2\u7570\u69cb\u9176I\u6291\u5236\u5291\uff0c\u53ef\u8a98\u5c0e\u816b\u7624\u7d30\u80deDNA\u640d\u50b7\uff0c\u9032\u800c\u5c0e\u81f4\u7d30\u80de\u9031\u671f\u963b\u6eef\u53ca\u7d30\u80de\u51cb\u4ea1\u3002\u6b64\u5916\uff0c\u5176\u4ea6\u65bc\u816b\u7624\u5fae\u74b0\u5883\u4e2d\u91cb\u653eKL610023\u3002\u9452\u65bcKL610023\u5177\u6709\u7d30\u80de\u819c\u6ef2\u900f\u6027\uff0c\u5176\u53ef\u5be6\u73fe\u65c1\u89c0\u8005\u6548\u61c9\uff0c\u5373\u6bba\u6b7b\u9130\u8fd1\u7684\u816b\u7624\u7d30\u80de\u3002 \u65bc2022\u5e745\u6708\uff0c\u516c\u53f8\u6388\u4e88\u9ed8\u6c99\u6771(\u7f8e\u570b\u65b0\u6fa4\u897f\u5dde\u7f85\u5a01\u5e02\u9ed8\u514b\u516c\u53f8\u7684\u5546\u865f)\u5728\u5927\u4e2d\u83ef\u5340(\u5305\u62ec\u4e2d\u570b\u5167\u5730\u3001\u9999\u6e2f\u3001\u6fb3\u9580\u53ca\u81fa\u7063)\u4ee5\u5916\u7684\u6240\u6709\u5730\u5340\u958b\u767c\u3001\u4f7f\u7528\u3001\u88fd\u9020\u53ca\u5546\u696d\u5316\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u7684\u7368\u5bb6\u6b0a\u5229\u3002 \u622a\u81f3\u76ee\u524d\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u76844\u9805\u9069\u61c9\u75c7\u5df2\u65bc\u4e2d\u570b\u7372\u6279\u4e0a\u5e02\uff0c\u5206\u5225\u7528\u65bc\uff1a\u7d93EGFR-TKI\u548c\u542b\u9251\u5316\u7642\u6cbb\u7642\u5f8c\u9032\u5c55\u7684EGFR\u57fa\u56e0\u7a81\u8b8a\u967d\u6027\u7684\u5c40\u90e8\u665a\u671f\u6216\u8f49\u79fb\u6027\u975e\u9c57\u72c0NSCLC\uff1b\u65e2\u5f80\u81f3\u5c11\u63a5\u53d7\u904e2\u7a2e\u7cfb\u7d71\u6cbb\u7642\uff08\u5176\u4e2d\u81f3\u5c111\u7a2e\u6cbb\u7642\u91dd\u5c0d\u665a\u671f\u6216\u8f49\u79fb\u6027\u968e\u6bb5\uff09\u7684\u4e0d\u53ef\u5207\u9664\u7684\u5c40\u90e8\u665a\u671f\u6216\u8f49\u79fb\u6027TNBC\uff1b\u7d93EGFR-TKI\u6cbb\u7642\u5f8c\u9032\u5c55\u7684EGFR\u57fa\u56e0\u7a81\u8b8a\u967d\u6027\u7684\u5c40\u90e8\u665a\u671f\u6216\u8f49\u79fb\u6027\u975e\u9c57\u72c0NSCLC\uff1b\u65e2\u5f80\u63a5\u53d7\u904e\u5167\u5206\u6ccc\u6cbb\u7642\u4e14\u5728\u665a\u671f\u75be\u75c5\u968e\u6bb5\u63a5\u53d7\u904e\u81f3\u5c11\u4e00\u7dda\u5316\u7642\u7684\u4e0d\u53ef\u5207\u9664\u6216\u8f49\u79fb\u6027\u7684HR+\/HER2- (IHC 0\u3001IHC 1+\u6216IHC 2+\/ISH-) BC\uff1b\u5176\u4e2d\u524d2\u9805\u9069\u61c9\u75c7\u5df2\u7d93\u88ab\u7d0d\u5165\u91ab\u4fdd\u7bc4\u570d\uff0c\u5c07\u70ba\u66f4\u591a\u4e73\u817a\u764c\u548c\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u60a3\u8005\u5e36\u4f86\u81e8\u5e8a\u7372\u76ca\u3002\u6b64\u5916\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u5df2\u7372NMPA\u6388\u4e886\u9805\u7a81\u7834\u6027\u7642\u6cd5\u8a8d\u5b9a(BTD)\u3002 \u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u662f\u5168\u7403\u9996\u500b\u5728\u80ba\u764c\u9069\u61c9\u75c7\u7372\u6279\u4e0a\u5e02\u7684TROP2 ADC\u85e5\u7269\u3002\u76ee\u524d\uff0c\u79d1\u502b\u535a\u6cf0\u5df2\u5728\u4e2d\u570b\u958b\u5c559\u9805\u8a3b\u518a\u6027\u81e8\u5e8a\u7814\u7a76\u3002\u9ed8\u6c99\u6771\u5df2\u4f48\u5c4017\u9805\u6b63\u5728\u9032\u884c\u7684\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u4f5c\u70ba\u55ae\u85e5\u7642\u6cd5\u6216\u806f\u5408\u5e15\u535a\u5229\u73e0\u55ae\u6297\u6216\u5176\u4ed6\u6297\u764c\u85e5\u7269\u7528\u65bc\u591a\u7a2e\u985e\u578b\u764c\u75c7\u7684\u5168\u7403\u6027III\u671f\u81e8\u5e8a\u7814\u7a76(\u9019\u4e9b\u7814\u7a76\u7531\u9ed8\u6c99\u6771\u7533\u8fa6\u4e26\u4e3b\u5c0e)\u3002 \u95dc\u65bc\u79d1\u502b\u535a\u6cf0 \u56db\u5ddd\u79d1\u502b\u535a\u6cf0\u751f\u7269\u91ab\u85e5\u80a1\u4efd\u6709\u9650\u516c\u53f8(\u7c21\u7a31\u300c\u79d1\u502b\u535a\u6cf0\u300d\uff0c\u80a1\u7968\u4ee3\u78bc\uff1a6990.HK)\u662f\u79d1\u502b\u85e5\u696d\u63a7\u80a1\u5b50\u516c\u53f8\uff0c\u5c08\u6ce8\u4e8e\u5275\u65b0\u751f\u7269\u6280\u8853\u85e5\u7269\u53ca\u5c0f\u5206\u5b50\u85e5\u7269\u7684\u7814\u767c\u3001\u751f\u7522\u3001\u5546\u696d\u5316\u53ca\u570b\u969b\u5408\u4f5c\u3002\u516c\u53f8\u570d\u7e5e\u5168\u7403\u548c\u4e2d\u570b\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\uff0c\u91cd\u9ede\u4f48\u5c40\u816b\u7624\u3001\u81ea\u8eab\u514d\u75ab\u548c\u4ee3\u8b1d\u7b49\u91cd\u5927\u75be\u75c5\u9818\u57df\uff0c\u5efa\u8a2d\u570b\u969b\u5316\u85e5\u7269\u7814\u767c\u8207\u7522\u696d\u5316\u5e73\u81fa\uff0c\u81f4\u529b\u65bc\u6210\u70ba\u5728\u5275\u65b0\u85e5\u7269\u9818\u57df\u570b\u969b\u9818\u5148\u7684\u4f01\u696d\u3002\u516c\u53f8\u76ee\u524d\u64c1\u670930\u4f59\u500b\u91cd\u9ede\u5275\u65b0\u85e5\u9805\u76ee\uff0c\u5176\u4e2d4\u500b\u9805\u76ee8\u500b\u9069\u61c9\u75c7\u5df2\u7372\u6279\u4e0a\u5e02\uff0c1\u500b\u5c08\u6848\u8655\u65bcNDA\u968e\u6bb5\uff0c10\u9918\u500b\u5c08\u6848\u6b63\u8655\u65bc\u81e8\u5e8a\u968e\u6bb5\u3002\u516c\u53f8\u6210\u529f\u69cb\u5efa\u4e86\u4eab\u8b7d\u570b\u969b\u7684\u5c08\u6709ADC\u53ca\u65b0\u578b\u5076\u806f\u85e5\u7269\u5e73\u81faOptiDCTM\uff0c\u5df2\u67092\u500bADC\u9805\u76ee5\u500b\u9069\u61c9\u75c7\u7372\u6279\u4e0a\u5e02\uff0c\u591a\u500bADC\u6216\u65b0\u578b\u5076\u806f\u85e5\u7269\u7522\u54c1\u8655\u65bc\u81e8\u5e8a\u6216\u81e8\u5e8a\u524d\u7814\u7a76\u968e\u6bb5\u3002 \u53c3\u8003\u4f86\u6e90\uff1a Fang W, Li X, Wang Q, et al. Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutant advanced non-small-cell lung cancer: open label, randomised, multicentre trial. BMJ. 2025 Jun 5:389:e085680. doi: 10.1136\/bmj-2025-085680. Fang W, Wu L, Meng X, et al. Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR-Mutated Advanced NSCLC. NEJM. 2026 Jan 1;394(1):13-26. doi: 10.1056\/NEJMoa2512071. Epub 2025 Oct 19.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pingtungtimes.com.tw\/?p=419001","og_locale":"zh_TW","og_type":"article","og_title":"\u7e3d\u751f\u5b58\u671f\u986f\u8457\u5ef6\u9577\uff1a\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT) OptiTROP-Lung03\u7814\u7a76OS\u6700\u7d42\u5206\u6790\u7d50\u679c\u4eae\u76f8 - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","og_description":"\u6210\u90fd2026\u5e743\u670818\u65e5 \/\u7f8e\u901a\u793e\/ -- 2026\u5e74\u6b50\u6d32\u80ba\u764c\u5927\u6703(ELCC)\u5c07\u65bc\u7576\u5730\u6642\u95933\u670825\u65e5\u81f328\u65e5\u5728\u4e39\u9ea5\u54e5\u672c\u54c8\u6839\u8209\u884c\u3002\u672c\u6b21\u6703\u8b70\u4e0a\uff0c\u56db\u5ddd\u79d1\u502b\u535a\u6cf0\u751f\u7269\u91ab\u85e5\u80a1\u4efd\u6709\u9650\u516c\u53f8(\u300c\u79d1\u502b\u535a\u6cf0\u300d\u6216\u300c\u516c\u53f8\u300d\uff0c6990.HK)\u81ea\u4e3b\u7814\u767c\u7684TROP2 ADC\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297( sac-TMT\uff0c\u4ea6\u7a31SKB264\/MK-2870)(\u4f73\u6cf0\u840a\u00ae)\u95dc\u9375\u81e8\u5e8a\u7814\u7a76(OptiTROP-Lung03)\u7684OS\u6700\u7d42\u5206\u6790\u7d50\u679c\u6210\u529f\u5165\u9078\u7a81\u7834\u6027\u6458\u8981(LBA)(\u5831\u544a\u7de8\u865f\uff1aLBA4)\uff0c\u5c46\u6642\u5c07\u7531\u4e2d\u5c71\u5927\u5b78\u816b\u7624\u9632\u6cbb\u4e2d\u5fc3\u694a\u96f2\u9d6c\u6559\u6388\u5728\u5c0f\u578b\u53e3\u982d\u5831\u544a\u5c08\u5834\uff08Mini Oral Session\uff09\u5411\u5168\u7403\u5b78\u8005\u5f59\u5831\u5206\u4eab\uff0c\u6458\u8981\u5df2\u767c\u4f48\u65bcESMO Open\u671f\u520a\u3002 OptiTROP-Lung03\u7814\u7a76\u65e8\u5728\u8a55\u4f30\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u55ae\u4e00\u7642\u6cd5(5 mg\/kg\u6bcf2\u9031\u4e00\u6b21) \u5c0d\u6bd4\u591a\u897f\u4ed6\u8cfd\uff0c\u5728\u65e2\u5f80\u63a5\u53d7\u904eEGFR-TKI\u548c\u542b\u9251\u5316\u7642\u6cbb\u7642\u7684\u5c40\u90e8\u665a\u671f\u6216\u8f49\u79fb\u6027EGFR\u7a81\u8b8a\u975e\u5c0f\u7d30\u80de\u80ba\u764c(NSCLC)\u60a3\u8005\u4e2d\u7684\u6709\u6548\u6027\u548c\u5b89\u5168\u6027\u3002\u6b64\u524d\u57282025\u5e74ASCO\u5e74\u6703\u4e0a\u516c\u4f48\u7684\u7d50\u679c\u986f\u793a\uff0c\u5728137\u4f8b\u96a8\u6a5f\u5165\u7d44\u7684\u60a3\u8005\u4e2d\uff0c\u76f8\u8f03\u65bc\u591a\u897f\u4ed6\u8cfd\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u5728\u7121\u9032\u5c55\u751f\u5b58\u671f(PFS\uff09\u548c\u7e3d\u751f\u5b58\u671f(OS)\u65b9\u9762\u5177\u6709\u986f\u8457\u7d71\u8a08\u5b78\u610f\u7fa9\u548c\u81e8\u5e8a\u610f\u7fa9\u7684\u6539\u5584\u2014\u2014\u7d93BICR\u8a55\u4f30\u7684PFS\u98a8\u96aa\u6bd4(HR)\u70ba0.30(95% CI: 0.20-0.46, \u55ae\u5074p<0.001)\uff1bOS\u7684HR\u70ba0.49(95% CI: 0.27-0.88, \u55ae\u5074p=0.007)\u3002\u57fa\u65bc\u9019\u4e00\u7a4d\u6975\u7d50\u679c\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u7372\u570b\u5bb6\u85e5\u54c1\u76e3\u7763\u7ba1\u7406\u5c40(NMPA)\u6279\u51c6\u6b64\u9069\u61c9\u75c7\uff0c\u8a72\u9069\u61c9\u75c7\u5df2\u88ab\u7d0d\u5165\u570b\u5bb6\u91ab\u4fdd\u76ee\u9304\u3002 2026 ELCC\u6703\u8b70\u5c07\u516c\u4f48OptiTROP-Lung03\u7814\u7a76\u7684OS\u6700\u7d42\u5206\u6790\u7d50\u679c\u53ca\u66f4\u65b0\u7684PFS\u8cc7\u6599\u7b49(\u622a\u81f32025\u5e7412\u670811\u65e5\uff0c\u4e2d\u4f4d\u96a8\u8a2a\u6642\u9593\u70ba23.8\u500b\u6708)\uff0c\u4e3b\u8981\u5167\u5bb9\u5982\u4e0b\uff1a \u591a\u897f\u4ed6\u8cfd\u6cbb\u7642\u5c0d\u7167\u7d44\uff0c\u670941.3%\u7684\u60a3\u8005\u5728\u75be\u75c5\u9032\u5c55\u5f8c\u9078\u64c7\u63a5\u53d7\u4e86\u5f8c\u7e8c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u6cbb\u7642\u3002 \u8003\u616e\u5c0d\u7167\u7d44\u4ea4\u53c9\u6cbb\u7642\u5c0dOS\u5f71\u97ff\uff0c\u63a1\u7528\u9810\u8a2d\u7684\u79e9\u4fdd\u6301\u7d50\u69cb\u5931\u6548\u6642\u9593(RPSFT)\u6a21\u578b\u9032\u884c\u6821\u6b63\u5206\u6790\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u7d44\u8207\u591a\u897f\u4ed6\u8cfd\u7d44\u4e2d\u4f4dOS\u5206\u5225\u70ba20.0\u500b\u6708 vs 11.2\u500b\u6708(HR 0.45, 95% CI : 0.28-0.73)\uff0c18\u500b\u6708OS\u7387\u5206\u5225\u70ba54.7% vs 9.1%\uff1b \u82e5\u5c0d\u7167\u7d44OS\u4e0d\u7d93\u5f8c\u7e8csac-TMT\u6cbb\u7642\u6821\u6b63\uff0c\u5169\u7d44\u7684\u4e2d\u4f4dOS\u5247\u70ba20.0\u500b\u6708 vs 13.5\u500b\u6708(HR 0.63, 95% CI: 0.40-0.98)\uff1b \u7814\u7a76\u8005(INV)\u8a55\u4f30\u7684\u4e2d\u4f4dPFS\u70ba7.9\u500b\u6708 vs 2.8\u500b\u6708(HR 0.23, 95% CI: 0.15-0.35)\u3002 \u503c\u5f97\u4e00\u63d0\u7684\u662f\uff0c\u57fa\u65bc\u53e6\u5916\u4e00\u9805OptiTROP-Lung04\u7814\u7a76\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT) \u5df2\u7372NMPA\u6279\u51c6\u7528\u65bc\u7d93EGFR-TKI\u6cbb\u7642\u5f8c\u9032\u5c55\u7684\u665a\u671f\u6216\u8f49\u79fb\u6027EGFR\u7a81\u8b8aNSCLC, \u76f8\u95dc\u7d50\u679c\u5df2\u540c\u6b65\u767c\u8868\u65bc\u300a\u65b0\u82f1\u683c\u862d\u91ab\u5b78\u96dc\u8a8c\u300b\u3002\u800c\u6b64\u6b21\u5728\u7d93EGFR-TKI\u548c\u542b\u9251\u5316\u7642\u6cbb\u7642\u5f8c\u9032\u5c55\u7684EGFRm NSCLC\u4eba\u7fa4\u4e2d\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297\u53d6\u5f97\u4e86\u5177\u6709\u986f\u8457\u7d71\u8a08\u5b78\u610f\u7fa9\u548c\u81e8\u5e8a\u610f\u7fa9\u7684\u751f\u5b58\u7372\u76ca\uff0c\u4e2d\u4f4dOS\u9577\u905420\u500b\u6708\u3002\u5169\u9805\u95dc\u9375\u8a3b\u518a\u7814\u7a76\u7684\u76f8\u7e7c\u9a57\u8b49\uff0c\u9032\u4e00\u6b65\u78ba\u7acb\u4e86\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u5728\u7d93\u6cbbEGFR\u7a81\u8b8aNSCLC\u6cbb\u7642\u9818\u57df\u7684\u9818\u5148\u5730\u4f4d\uff0c\u70ba\u665a\u671f\u80ba\u764c\u60a3\u8005\u63d0\u4f9b\u4e86\u66f4\u5177\u78ba\u5b9a\u6027\u8207\u9577\u671f\u751f\u5b58\u7372\u76ca\u7684\u6cbb\u7642\u9078\u64c7\u3002 \u95dc\u65bc\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)(\u4f73\u6cf0\u840a\u00ae) \u4f5c\u70ba\u516c\u53f8\u7684\u6838\u5fc3\u7522\u54c1\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u662f\u4e00\u6b3e\u516c\u53f8\u64c1\u6709\u81ea\u4e3b\u667a\u6167\u8ca1\u7522\u6b0a\u7684\u65b0\u578bTROP2 ADC\uff0c\u91dd\u5c0dNSCLC\u3001\u4e73\u817a\u764c(BC)\u3001\u80c3\u764c(GC)\u3001\u5a66\u79d1\u816b\u7624\u7b49\u665a\u671f\u5be6\u9ad4\u7624\u3002\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u63a1\u7528\u65b0\u578b\u9023\u63a5\u5b50\u9032\u884c\u958b\u767c\uff0c\u5176\u901a\u904e\u5076\u806f\u4e00\u7a2e\u8c9d\u6d1b\u66ff\u5eb7\u884d\u751f\u7684\u62d3\u64b2\u7570\u69cb\u9176I\u6291\u5236\u5291\u4f5c\u70ba\u6709\u6548\u8f09\u8377\uff0c\u85e5\u7269\u6297\u9ad4\u6bd4(DAR)\u9054\u52307.4\u3002\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u901a\u904e\u91cd\u7d44\u6297TROP2\u4eba\u6e90\u5316\u55ae\u514b\u9686\u6297\u9ad4\u7279\u7570\u6027\u8b58\u5225\u816b\u7624\u7d30\u80de\u8868\u9762\u7684TROP2\uff0c\u5176\u5f8c\u88ab\u816b\u7624\u7d30\u80de\u5167\u541e\u4f75\u65bc\u7d30\u80de\u5167\u91cb\u653e\u6709\u6548\u8f09\u8377KL610023\u3002KL610023\u4f5c\u70ba\u62d3\u64b2\u7570\u69cb\u9176I\u6291\u5236\u5291\uff0c\u53ef\u8a98\u5c0e\u816b\u7624\u7d30\u80deDNA\u640d\u50b7\uff0c\u9032\u800c\u5c0e\u81f4\u7d30\u80de\u9031\u671f\u963b\u6eef\u53ca\u7d30\u80de\u51cb\u4ea1\u3002\u6b64\u5916\uff0c\u5176\u4ea6\u65bc\u816b\u7624\u5fae\u74b0\u5883\u4e2d\u91cb\u653eKL610023\u3002\u9452\u65bcKL610023\u5177\u6709\u7d30\u80de\u819c\u6ef2\u900f\u6027\uff0c\u5176\u53ef\u5be6\u73fe\u65c1\u89c0\u8005\u6548\u61c9\uff0c\u5373\u6bba\u6b7b\u9130\u8fd1\u7684\u816b\u7624\u7d30\u80de\u3002 \u65bc2022\u5e745\u6708\uff0c\u516c\u53f8\u6388\u4e88\u9ed8\u6c99\u6771(\u7f8e\u570b\u65b0\u6fa4\u897f\u5dde\u7f85\u5a01\u5e02\u9ed8\u514b\u516c\u53f8\u7684\u5546\u865f)\u5728\u5927\u4e2d\u83ef\u5340(\u5305\u62ec\u4e2d\u570b\u5167\u5730\u3001\u9999\u6e2f\u3001\u6fb3\u9580\u53ca\u81fa\u7063)\u4ee5\u5916\u7684\u6240\u6709\u5730\u5340\u958b\u767c\u3001\u4f7f\u7528\u3001\u88fd\u9020\u53ca\u5546\u696d\u5316\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u7684\u7368\u5bb6\u6b0a\u5229\u3002 \u622a\u81f3\u76ee\u524d\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u76844\u9805\u9069\u61c9\u75c7\u5df2\u65bc\u4e2d\u570b\u7372\u6279\u4e0a\u5e02\uff0c\u5206\u5225\u7528\u65bc\uff1a\u7d93EGFR-TKI\u548c\u542b\u9251\u5316\u7642\u6cbb\u7642\u5f8c\u9032\u5c55\u7684EGFR\u57fa\u56e0\u7a81\u8b8a\u967d\u6027\u7684\u5c40\u90e8\u665a\u671f\u6216\u8f49\u79fb\u6027\u975e\u9c57\u72c0NSCLC\uff1b\u65e2\u5f80\u81f3\u5c11\u63a5\u53d7\u904e2\u7a2e\u7cfb\u7d71\u6cbb\u7642\uff08\u5176\u4e2d\u81f3\u5c111\u7a2e\u6cbb\u7642\u91dd\u5c0d\u665a\u671f\u6216\u8f49\u79fb\u6027\u968e\u6bb5\uff09\u7684\u4e0d\u53ef\u5207\u9664\u7684\u5c40\u90e8\u665a\u671f\u6216\u8f49\u79fb\u6027TNBC\uff1b\u7d93EGFR-TKI\u6cbb\u7642\u5f8c\u9032\u5c55\u7684EGFR\u57fa\u56e0\u7a81\u8b8a\u967d\u6027\u7684\u5c40\u90e8\u665a\u671f\u6216\u8f49\u79fb\u6027\u975e\u9c57\u72c0NSCLC\uff1b\u65e2\u5f80\u63a5\u53d7\u904e\u5167\u5206\u6ccc\u6cbb\u7642\u4e14\u5728\u665a\u671f\u75be\u75c5\u968e\u6bb5\u63a5\u53d7\u904e\u81f3\u5c11\u4e00\u7dda\u5316\u7642\u7684\u4e0d\u53ef\u5207\u9664\u6216\u8f49\u79fb\u6027\u7684HR+\/HER2- (IHC 0\u3001IHC 1+\u6216IHC 2+\/ISH-) BC\uff1b\u5176\u4e2d\u524d2\u9805\u9069\u61c9\u75c7\u5df2\u7d93\u88ab\u7d0d\u5165\u91ab\u4fdd\u7bc4\u570d\uff0c\u5c07\u70ba\u66f4\u591a\u4e73\u817a\u764c\u548c\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u60a3\u8005\u5e36\u4f86\u81e8\u5e8a\u7372\u76ca\u3002\u6b64\u5916\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u5df2\u7372NMPA\u6388\u4e886\u9805\u7a81\u7834\u6027\u7642\u6cd5\u8a8d\u5b9a(BTD)\u3002 \u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u662f\u5168\u7403\u9996\u500b\u5728\u80ba\u764c\u9069\u61c9\u75c7\u7372\u6279\u4e0a\u5e02\u7684TROP2 ADC\u85e5\u7269\u3002\u76ee\u524d\uff0c\u79d1\u502b\u535a\u6cf0\u5df2\u5728\u4e2d\u570b\u958b\u5c559\u9805\u8a3b\u518a\u6027\u81e8\u5e8a\u7814\u7a76\u3002\u9ed8\u6c99\u6771\u5df2\u4f48\u5c4017\u9805\u6b63\u5728\u9032\u884c\u7684\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u4f5c\u70ba\u55ae\u85e5\u7642\u6cd5\u6216\u806f\u5408\u5e15\u535a\u5229\u73e0\u55ae\u6297\u6216\u5176\u4ed6\u6297\u764c\u85e5\u7269\u7528\u65bc\u591a\u7a2e\u985e\u578b\u764c\u75c7\u7684\u5168\u7403\u6027III\u671f\u81e8\u5e8a\u7814\u7a76(\u9019\u4e9b\u7814\u7a76\u7531\u9ed8\u6c99\u6771\u7533\u8fa6\u4e26\u4e3b\u5c0e)\u3002 \u95dc\u65bc\u79d1\u502b\u535a\u6cf0 \u56db\u5ddd\u79d1\u502b\u535a\u6cf0\u751f\u7269\u91ab\u85e5\u80a1\u4efd\u6709\u9650\u516c\u53f8(\u7c21\u7a31\u300c\u79d1\u502b\u535a\u6cf0\u300d\uff0c\u80a1\u7968\u4ee3\u78bc\uff1a6990.HK)\u662f\u79d1\u502b\u85e5\u696d\u63a7\u80a1\u5b50\u516c\u53f8\uff0c\u5c08\u6ce8\u4e8e\u5275\u65b0\u751f\u7269\u6280\u8853\u85e5\u7269\u53ca\u5c0f\u5206\u5b50\u85e5\u7269\u7684\u7814\u767c\u3001\u751f\u7522\u3001\u5546\u696d\u5316\u53ca\u570b\u969b\u5408\u4f5c\u3002\u516c\u53f8\u570d\u7e5e\u5168\u7403\u548c\u4e2d\u570b\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\uff0c\u91cd\u9ede\u4f48\u5c40\u816b\u7624\u3001\u81ea\u8eab\u514d\u75ab\u548c\u4ee3\u8b1d\u7b49\u91cd\u5927\u75be\u75c5\u9818\u57df\uff0c\u5efa\u8a2d\u570b\u969b\u5316\u85e5\u7269\u7814\u767c\u8207\u7522\u696d\u5316\u5e73\u81fa\uff0c\u81f4\u529b\u65bc\u6210\u70ba\u5728\u5275\u65b0\u85e5\u7269\u9818\u57df\u570b\u969b\u9818\u5148\u7684\u4f01\u696d\u3002\u516c\u53f8\u76ee\u524d\u64c1\u670930\u4f59\u500b\u91cd\u9ede\u5275\u65b0\u85e5\u9805\u76ee\uff0c\u5176\u4e2d4\u500b\u9805\u76ee8\u500b\u9069\u61c9\u75c7\u5df2\u7372\u6279\u4e0a\u5e02\uff0c1\u500b\u5c08\u6848\u8655\u65bcNDA\u968e\u6bb5\uff0c10\u9918\u500b\u5c08\u6848\u6b63\u8655\u65bc\u81e8\u5e8a\u968e\u6bb5\u3002\u516c\u53f8\u6210\u529f\u69cb\u5efa\u4e86\u4eab\u8b7d\u570b\u969b\u7684\u5c08\u6709ADC\u53ca\u65b0\u578b\u5076\u806f\u85e5\u7269\u5e73\u81faOptiDCTM\uff0c\u5df2\u67092\u500bADC\u9805\u76ee5\u500b\u9069\u61c9\u75c7\u7372\u6279\u4e0a\u5e02\uff0c\u591a\u500bADC\u6216\u65b0\u578b\u5076\u806f\u85e5\u7269\u7522\u54c1\u8655\u65bc\u81e8\u5e8a\u6216\u81e8\u5e8a\u524d\u7814\u7a76\u968e\u6bb5\u3002 \u53c3\u8003\u4f86\u6e90\uff1a Fang W, Li X, Wang Q, et al. Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutant advanced non-small-cell lung cancer: open label, randomised, multicentre trial. BMJ. 2025 Jun 5:389:e085680. doi: 10.1136\/bmj-2025-085680. Fang W, Wu L, Meng X, et al. Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR-Mutated Advanced NSCLC. NEJM. 2026 Jan 1;394(1):13-26. doi: 10.1056\/NEJMoa2512071. Epub 2025 Oct 19.","og_url":"https:\/\/pingtungtimes.com.tw\/?p=419001","og_site_name":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","article_publisher":"https:\/\/www.facebook.com\/pingtungnews","article_published_time":"2026-03-18T15:22:00+00:00","og_image":[{"width":3000,"height":1990,"url":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png","type":"image\/jpeg"}],"author":"\u7f8e\u901a\u793e","twitter_card":"summary_large_image","twitter_misc":{"\u4f5c\u8005:":"\u7f8e\u901a\u793e","\u9810\u4f30\u95b1\u8b80\u6642\u9593":"1 \u5206\u9418"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/pingtungtimes.com.tw\/?p=419001#article","isPartOf":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=419001"},"author":{"name":"\u7f8e\u901a\u793e","@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/person\/683b937f29ec1537972f6c41e22a2cf3"},"headline":"\u7e3d\u751f\u5b58\u671f\u986f\u8457\u5ef6\u9577\uff1a\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT) OptiTROP-Lung03\u7814\u7a76OS\u6700\u7d42\u5206\u6790\u7d50\u679c\u4eae\u76f8","datePublished":"2026-03-18T15:22:00+00:00","mainEntityOfPage":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=419001"},"wordCount":191,"publisher":{"@id":"https:\/\/pingtungtimes.com.tw\/#organization"},"image":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=419001#primaryimage"},"thumbnailUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2026\/03\/1-17.jpg","articleSection":["\u7f8e\u901a\u793e"],"inLanguage":"zh-TW"},{"@type":"WebPage","@id":"https:\/\/pingtungtimes.com.tw\/?p=419001","url":"https:\/\/pingtungtimes.com.tw\/?p=419001","name":"\u7e3d\u751f\u5b58\u671f\u986f\u8457\u5ef6\u9577\uff1a\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT) OptiTROP-Lung03\u7814\u7a76OS\u6700\u7d42\u5206\u6790\u7d50\u679c\u4eae\u76f8 - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","isPartOf":{"@id":"https:\/\/pingtungtimes.com.tw\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=419001#primaryimage"},"image":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=419001#primaryimage"},"thumbnailUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2026\/03\/1-17.jpg","datePublished":"2026-03-18T15:22:00+00:00","description":"\u6210\u90fd2026\u5e743\u670818\u65e5 \/\u7f8e\u901a\u793e\/ -- 2026\u5e74\u6b50\u6d32\u80ba\u764c\u5927\u6703(ELCC)\u5c07\u65bc\u7576\u5730\u6642\u95933\u670825\u65e5\u81f328\u65e5\u5728\u4e39\u9ea5\u54e5\u672c\u54c8\u6839\u8209\u884c\u3002\u672c\u6b21\u6703\u8b70\u4e0a\uff0c\u56db\u5ddd\u79d1\u502b\u535a\u6cf0\u751f\u7269\u91ab\u85e5\u80a1\u4efd\u6709\u9650\u516c\u53f8(\u300c\u79d1\u502b\u535a\u6cf0\u300d\u6216\u300c\u516c\u53f8\u300d\uff0c6990.HK)\u81ea\u4e3b\u7814\u767c\u7684TROP2 ADC\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297( sac-TMT\uff0c\u4ea6\u7a31SKB264\/MK-2870)(\u4f73\u6cf0\u840a\u00ae)\u95dc\u9375\u81e8\u5e8a\u7814\u7a76(OptiTROP-Lung03)\u7684OS\u6700\u7d42\u5206\u6790\u7d50\u679c\u6210\u529f\u5165\u9078\u7a81\u7834\u6027\u6458\u8981(LBA)(\u5831\u544a\u7de8\u865f\uff1aLBA4)\uff0c\u5c46\u6642\u5c07\u7531\u4e2d\u5c71\u5927\u5b78\u816b\u7624\u9632\u6cbb\u4e2d\u5fc3\u694a\u96f2\u9d6c\u6559\u6388\u5728\u5c0f\u578b\u53e3\u982d\u5831\u544a\u5c08\u5834\uff08Mini Oral Session\uff09\u5411\u5168\u7403\u5b78\u8005\u5f59\u5831\u5206\u4eab\uff0c\u6458\u8981\u5df2\u767c\u4f48\u65bcESMO Open\u671f\u520a\u3002 OptiTROP-Lung03\u7814\u7a76\u65e8\u5728\u8a55\u4f30\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u55ae\u4e00\u7642\u6cd5(5 mg\/kg\u6bcf2\u9031\u4e00\u6b21) \u5c0d\u6bd4\u591a\u897f\u4ed6\u8cfd\uff0c\u5728\u65e2\u5f80\u63a5\u53d7\u904eEGFR-TKI\u548c\u542b\u9251\u5316\u7642\u6cbb\u7642\u7684\u5c40\u90e8\u665a\u671f\u6216\u8f49\u79fb\u6027EGFR\u7a81\u8b8a\u975e\u5c0f\u7d30\u80de\u80ba\u764c(NSCLC)\u60a3\u8005\u4e2d\u7684\u6709\u6548\u6027\u548c\u5b89\u5168\u6027\u3002\u6b64\u524d\u57282025\u5e74ASCO\u5e74\u6703\u4e0a\u516c\u4f48\u7684\u7d50\u679c\u986f\u793a\uff0c\u5728137\u4f8b\u96a8\u6a5f\u5165\u7d44\u7684\u60a3\u8005\u4e2d\uff0c\u76f8\u8f03\u65bc\u591a\u897f\u4ed6\u8cfd\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u5728\u7121\u9032\u5c55\u751f\u5b58\u671f(PFS\uff09\u548c\u7e3d\u751f\u5b58\u671f(OS)\u65b9\u9762\u5177\u6709\u986f\u8457\u7d71\u8a08\u5b78\u610f\u7fa9\u548c\u81e8\u5e8a\u610f\u7fa9\u7684\u6539\u5584\u2014\u2014\u7d93BICR\u8a55\u4f30\u7684PFS\u98a8\u96aa\u6bd4(HR)\u70ba0.30(95% CI: 0.20-0.46, \u55ae\u5074p<0.001)\uff1bOS\u7684HR\u70ba0.49(95% CI: 0.27-0.88, \u55ae\u5074p=0.007)\u3002\u57fa\u65bc\u9019\u4e00\u7a4d\u6975\u7d50\u679c\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u7372\u570b\u5bb6\u85e5\u54c1\u76e3\u7763\u7ba1\u7406\u5c40(NMPA)\u6279\u51c6\u6b64\u9069\u61c9\u75c7\uff0c\u8a72\u9069\u61c9\u75c7\u5df2\u88ab\u7d0d\u5165\u570b\u5bb6\u91ab\u4fdd\u76ee\u9304\u3002 2026 ELCC\u6703\u8b70\u5c07\u516c\u4f48OptiTROP-Lung03\u7814\u7a76\u7684OS\u6700\u7d42\u5206\u6790\u7d50\u679c\u53ca\u66f4\u65b0\u7684PFS\u8cc7\u6599\u7b49(\u622a\u81f32025\u5e7412\u670811\u65e5\uff0c\u4e2d\u4f4d\u96a8\u8a2a\u6642\u9593\u70ba23.8\u500b\u6708)\uff0c\u4e3b\u8981\u5167\u5bb9\u5982\u4e0b\uff1a \u591a\u897f\u4ed6\u8cfd\u6cbb\u7642\u5c0d\u7167\u7d44\uff0c\u670941.3%\u7684\u60a3\u8005\u5728\u75be\u75c5\u9032\u5c55\u5f8c\u9078\u64c7\u63a5\u53d7\u4e86\u5f8c\u7e8c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u6cbb\u7642\u3002 \u8003\u616e\u5c0d\u7167\u7d44\u4ea4\u53c9\u6cbb\u7642\u5c0dOS\u5f71\u97ff\uff0c\u63a1\u7528\u9810\u8a2d\u7684\u79e9\u4fdd\u6301\u7d50\u69cb\u5931\u6548\u6642\u9593(RPSFT)\u6a21\u578b\u9032\u884c\u6821\u6b63\u5206\u6790\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u7d44\u8207\u591a\u897f\u4ed6\u8cfd\u7d44\u4e2d\u4f4dOS\u5206\u5225\u70ba20.0\u500b\u6708 vs 11.2\u500b\u6708(HR 0.45, 95% CI : 0.28-0.73)\uff0c18\u500b\u6708OS\u7387\u5206\u5225\u70ba54.7% vs 9.1%\uff1b \u82e5\u5c0d\u7167\u7d44OS\u4e0d\u7d93\u5f8c\u7e8csac-TMT\u6cbb\u7642\u6821\u6b63\uff0c\u5169\u7d44\u7684\u4e2d\u4f4dOS\u5247\u70ba20.0\u500b\u6708 vs 13.5\u500b\u6708(HR 0.63, 95% CI: 0.40-0.98)\uff1b \u7814\u7a76\u8005(INV)\u8a55\u4f30\u7684\u4e2d\u4f4dPFS\u70ba7.9\u500b\u6708 vs 2.8\u500b\u6708(HR 0.23, 95% CI: 0.15-0.35)\u3002 \u503c\u5f97\u4e00\u63d0\u7684\u662f\uff0c\u57fa\u65bc\u53e6\u5916\u4e00\u9805OptiTROP-Lung04\u7814\u7a76\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT) \u5df2\u7372NMPA\u6279\u51c6\u7528\u65bc\u7d93EGFR-TKI\u6cbb\u7642\u5f8c\u9032\u5c55\u7684\u665a\u671f\u6216\u8f49\u79fb\u6027EGFR\u7a81\u8b8aNSCLC, \u76f8\u95dc\u7d50\u679c\u5df2\u540c\u6b65\u767c\u8868\u65bc\u300a\u65b0\u82f1\u683c\u862d\u91ab\u5b78\u96dc\u8a8c\u300b\u3002\u800c\u6b64\u6b21\u5728\u7d93EGFR-TKI\u548c\u542b\u9251\u5316\u7642\u6cbb\u7642\u5f8c\u9032\u5c55\u7684EGFRm NSCLC\u4eba\u7fa4\u4e2d\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297\u53d6\u5f97\u4e86\u5177\u6709\u986f\u8457\u7d71\u8a08\u5b78\u610f\u7fa9\u548c\u81e8\u5e8a\u610f\u7fa9\u7684\u751f\u5b58\u7372\u76ca\uff0c\u4e2d\u4f4dOS\u9577\u905420\u500b\u6708\u3002\u5169\u9805\u95dc\u9375\u8a3b\u518a\u7814\u7a76\u7684\u76f8\u7e7c\u9a57\u8b49\uff0c\u9032\u4e00\u6b65\u78ba\u7acb\u4e86\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u5728\u7d93\u6cbbEGFR\u7a81\u8b8aNSCLC\u6cbb\u7642\u9818\u57df\u7684\u9818\u5148\u5730\u4f4d\uff0c\u70ba\u665a\u671f\u80ba\u764c\u60a3\u8005\u63d0\u4f9b\u4e86\u66f4\u5177\u78ba\u5b9a\u6027\u8207\u9577\u671f\u751f\u5b58\u7372\u76ca\u7684\u6cbb\u7642\u9078\u64c7\u3002 \u95dc\u65bc\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)(\u4f73\u6cf0\u840a\u00ae) \u4f5c\u70ba\u516c\u53f8\u7684\u6838\u5fc3\u7522\u54c1\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u662f\u4e00\u6b3e\u516c\u53f8\u64c1\u6709\u81ea\u4e3b\u667a\u6167\u8ca1\u7522\u6b0a\u7684\u65b0\u578bTROP2 ADC\uff0c\u91dd\u5c0dNSCLC\u3001\u4e73\u817a\u764c(BC)\u3001\u80c3\u764c(GC)\u3001\u5a66\u79d1\u816b\u7624\u7b49\u665a\u671f\u5be6\u9ad4\u7624\u3002\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u63a1\u7528\u65b0\u578b\u9023\u63a5\u5b50\u9032\u884c\u958b\u767c\uff0c\u5176\u901a\u904e\u5076\u806f\u4e00\u7a2e\u8c9d\u6d1b\u66ff\u5eb7\u884d\u751f\u7684\u62d3\u64b2\u7570\u69cb\u9176I\u6291\u5236\u5291\u4f5c\u70ba\u6709\u6548\u8f09\u8377\uff0c\u85e5\u7269\u6297\u9ad4\u6bd4(DAR)\u9054\u52307.4\u3002\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u901a\u904e\u91cd\u7d44\u6297TROP2\u4eba\u6e90\u5316\u55ae\u514b\u9686\u6297\u9ad4\u7279\u7570\u6027\u8b58\u5225\u816b\u7624\u7d30\u80de\u8868\u9762\u7684TROP2\uff0c\u5176\u5f8c\u88ab\u816b\u7624\u7d30\u80de\u5167\u541e\u4f75\u65bc\u7d30\u80de\u5167\u91cb\u653e\u6709\u6548\u8f09\u8377KL610023\u3002KL610023\u4f5c\u70ba\u62d3\u64b2\u7570\u69cb\u9176I\u6291\u5236\u5291\uff0c\u53ef\u8a98\u5c0e\u816b\u7624\u7d30\u80deDNA\u640d\u50b7\uff0c\u9032\u800c\u5c0e\u81f4\u7d30\u80de\u9031\u671f\u963b\u6eef\u53ca\u7d30\u80de\u51cb\u4ea1\u3002\u6b64\u5916\uff0c\u5176\u4ea6\u65bc\u816b\u7624\u5fae\u74b0\u5883\u4e2d\u91cb\u653eKL610023\u3002\u9452\u65bcKL610023\u5177\u6709\u7d30\u80de\u819c\u6ef2\u900f\u6027\uff0c\u5176\u53ef\u5be6\u73fe\u65c1\u89c0\u8005\u6548\u61c9\uff0c\u5373\u6bba\u6b7b\u9130\u8fd1\u7684\u816b\u7624\u7d30\u80de\u3002 \u65bc2022\u5e745\u6708\uff0c\u516c\u53f8\u6388\u4e88\u9ed8\u6c99\u6771(\u7f8e\u570b\u65b0\u6fa4\u897f\u5dde\u7f85\u5a01\u5e02\u9ed8\u514b\u516c\u53f8\u7684\u5546\u865f)\u5728\u5927\u4e2d\u83ef\u5340(\u5305\u62ec\u4e2d\u570b\u5167\u5730\u3001\u9999\u6e2f\u3001\u6fb3\u9580\u53ca\u81fa\u7063)\u4ee5\u5916\u7684\u6240\u6709\u5730\u5340\u958b\u767c\u3001\u4f7f\u7528\u3001\u88fd\u9020\u53ca\u5546\u696d\u5316\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u7684\u7368\u5bb6\u6b0a\u5229\u3002 \u622a\u81f3\u76ee\u524d\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u76844\u9805\u9069\u61c9\u75c7\u5df2\u65bc\u4e2d\u570b\u7372\u6279\u4e0a\u5e02\uff0c\u5206\u5225\u7528\u65bc\uff1a\u7d93EGFR-TKI\u548c\u542b\u9251\u5316\u7642\u6cbb\u7642\u5f8c\u9032\u5c55\u7684EGFR\u57fa\u56e0\u7a81\u8b8a\u967d\u6027\u7684\u5c40\u90e8\u665a\u671f\u6216\u8f49\u79fb\u6027\u975e\u9c57\u72c0NSCLC\uff1b\u65e2\u5f80\u81f3\u5c11\u63a5\u53d7\u904e2\u7a2e\u7cfb\u7d71\u6cbb\u7642\uff08\u5176\u4e2d\u81f3\u5c111\u7a2e\u6cbb\u7642\u91dd\u5c0d\u665a\u671f\u6216\u8f49\u79fb\u6027\u968e\u6bb5\uff09\u7684\u4e0d\u53ef\u5207\u9664\u7684\u5c40\u90e8\u665a\u671f\u6216\u8f49\u79fb\u6027TNBC\uff1b\u7d93EGFR-TKI\u6cbb\u7642\u5f8c\u9032\u5c55\u7684EGFR\u57fa\u56e0\u7a81\u8b8a\u967d\u6027\u7684\u5c40\u90e8\u665a\u671f\u6216\u8f49\u79fb\u6027\u975e\u9c57\u72c0NSCLC\uff1b\u65e2\u5f80\u63a5\u53d7\u904e\u5167\u5206\u6ccc\u6cbb\u7642\u4e14\u5728\u665a\u671f\u75be\u75c5\u968e\u6bb5\u63a5\u53d7\u904e\u81f3\u5c11\u4e00\u7dda\u5316\u7642\u7684\u4e0d\u53ef\u5207\u9664\u6216\u8f49\u79fb\u6027\u7684HR+\/HER2- (IHC 0\u3001IHC 1+\u6216IHC 2+\/ISH-) BC\uff1b\u5176\u4e2d\u524d2\u9805\u9069\u61c9\u75c7\u5df2\u7d93\u88ab\u7d0d\u5165\u91ab\u4fdd\u7bc4\u570d\uff0c\u5c07\u70ba\u66f4\u591a\u4e73\u817a\u764c\u548c\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u60a3\u8005\u5e36\u4f86\u81e8\u5e8a\u7372\u76ca\u3002\u6b64\u5916\uff0c\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u5df2\u7372NMPA\u6388\u4e886\u9805\u7a81\u7834\u6027\u7642\u6cd5\u8a8d\u5b9a(BTD)\u3002 \u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u662f\u5168\u7403\u9996\u500b\u5728\u80ba\u764c\u9069\u61c9\u75c7\u7372\u6279\u4e0a\u5e02\u7684TROP2 ADC\u85e5\u7269\u3002\u76ee\u524d\uff0c\u79d1\u502b\u535a\u6cf0\u5df2\u5728\u4e2d\u570b\u958b\u5c559\u9805\u8a3b\u518a\u6027\u81e8\u5e8a\u7814\u7a76\u3002\u9ed8\u6c99\u6771\u5df2\u4f48\u5c4017\u9805\u6b63\u5728\u9032\u884c\u7684\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT)\u4f5c\u70ba\u55ae\u85e5\u7642\u6cd5\u6216\u806f\u5408\u5e15\u535a\u5229\u73e0\u55ae\u6297\u6216\u5176\u4ed6\u6297\u764c\u85e5\u7269\u7528\u65bc\u591a\u7a2e\u985e\u578b\u764c\u75c7\u7684\u5168\u7403\u6027III\u671f\u81e8\u5e8a\u7814\u7a76(\u9019\u4e9b\u7814\u7a76\u7531\u9ed8\u6c99\u6771\u7533\u8fa6\u4e26\u4e3b\u5c0e)\u3002 \u95dc\u65bc\u79d1\u502b\u535a\u6cf0 \u56db\u5ddd\u79d1\u502b\u535a\u6cf0\u751f\u7269\u91ab\u85e5\u80a1\u4efd\u6709\u9650\u516c\u53f8(\u7c21\u7a31\u300c\u79d1\u502b\u535a\u6cf0\u300d\uff0c\u80a1\u7968\u4ee3\u78bc\uff1a6990.HK)\u662f\u79d1\u502b\u85e5\u696d\u63a7\u80a1\u5b50\u516c\u53f8\uff0c\u5c08\u6ce8\u4e8e\u5275\u65b0\u751f\u7269\u6280\u8853\u85e5\u7269\u53ca\u5c0f\u5206\u5b50\u85e5\u7269\u7684\u7814\u767c\u3001\u751f\u7522\u3001\u5546\u696d\u5316\u53ca\u570b\u969b\u5408\u4f5c\u3002\u516c\u53f8\u570d\u7e5e\u5168\u7403\u548c\u4e2d\u570b\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\uff0c\u91cd\u9ede\u4f48\u5c40\u816b\u7624\u3001\u81ea\u8eab\u514d\u75ab\u548c\u4ee3\u8b1d\u7b49\u91cd\u5927\u75be\u75c5\u9818\u57df\uff0c\u5efa\u8a2d\u570b\u969b\u5316\u85e5\u7269\u7814\u767c\u8207\u7522\u696d\u5316\u5e73\u81fa\uff0c\u81f4\u529b\u65bc\u6210\u70ba\u5728\u5275\u65b0\u85e5\u7269\u9818\u57df\u570b\u969b\u9818\u5148\u7684\u4f01\u696d\u3002\u516c\u53f8\u76ee\u524d\u64c1\u670930\u4f59\u500b\u91cd\u9ede\u5275\u65b0\u85e5\u9805\u76ee\uff0c\u5176\u4e2d4\u500b\u9805\u76ee8\u500b\u9069\u61c9\u75c7\u5df2\u7372\u6279\u4e0a\u5e02\uff0c1\u500b\u5c08\u6848\u8655\u65bcNDA\u968e\u6bb5\uff0c10\u9918\u500b\u5c08\u6848\u6b63\u8655\u65bc\u81e8\u5e8a\u968e\u6bb5\u3002\u516c\u53f8\u6210\u529f\u69cb\u5efa\u4e86\u4eab\u8b7d\u570b\u969b\u7684\u5c08\u6709ADC\u53ca\u65b0\u578b\u5076\u806f\u85e5\u7269\u5e73\u81faOptiDCTM\uff0c\u5df2\u67092\u500bADC\u9805\u76ee5\u500b\u9069\u61c9\u75c7\u7372\u6279\u4e0a\u5e02\uff0c\u591a\u500bADC\u6216\u65b0\u578b\u5076\u806f\u85e5\u7269\u7522\u54c1\u8655\u65bc\u81e8\u5e8a\u6216\u81e8\u5e8a\u524d\u7814\u7a76\u968e\u6bb5\u3002 \u53c3\u8003\u4f86\u6e90\uff1a Fang W, Li X, Wang Q, et al. Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutant advanced non-small-cell lung cancer: open label, randomised, multicentre trial. BMJ. 2025 Jun 5:389:e085680. doi: 10.1136\/bmj-2025-085680. Fang W, Wu L, Meng X, et al. Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR-Mutated Advanced NSCLC. NEJM. 2026 Jan 1;394(1):13-26. doi: 10.1056\/NEJMoa2512071. Epub 2025 Oct 19.","breadcrumb":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=419001#breadcrumb"},"inLanguage":"zh-TW","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pingtungtimes.com.tw\/?p=419001"]}]},{"@type":"ImageObject","inLanguage":"zh-TW","@id":"https:\/\/pingtungtimes.com.tw\/?p=419001#primaryimage","url":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2026\/03\/1-17.jpg","contentUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2026\/03\/1-17.jpg","width":400,"height":91},{"@type":"BreadcrumbList","@id":"https:\/\/pingtungtimes.com.tw\/?p=419001#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"\u9996\u9801","item":"https:\/\/pingtungtimes.com.tw\/"},{"@type":"ListItem","position":2,"name":"\u7e3d\u751f\u5b58\u671f\u986f\u8457\u5ef6\u9577\uff1a\u8606\u5eb7\u6c99\u59a5\u73e0\u55ae\u6297(sac-TMT) OptiTROP-Lung03\u7814\u7a76OS\u6700\u7d42\u5206\u6790\u7d50\u679c\u4eae\u76f8"}]},{"@type":"WebSite","@id":"https:\/\/pingtungtimes.com.tw\/#website","url":"https:\/\/pingtungtimes.com.tw\/","name":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","description":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831PingtungTimes\uff0c\u6700\u95dc\u5fc3\u5728\u5730\u7684\u5a92\u9ad4","publisher":{"@id":"https:\/\/pingtungtimes.com.tw\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pingtungtimes.com.tw\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-TW"},{"@type":"Organization","@id":"https:\/\/pingtungtimes.com.tw\/#organization","name":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","url":"https:\/\/pingtungtimes.com.tw\/","logo":{"@type":"ImageObject","inLanguage":"zh-TW","@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/logo\/image\/","url":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png","contentUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png","width":150,"height":150,"caption":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831"},"image":{"@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/pingtungnews"]},{"@type":"Person","@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/person\/683b937f29ec1537972f6c41e22a2cf3","name":"\u7f8e\u901a\u793e","image":{"@type":"ImageObject","inLanguage":"zh-TW","@id":"https:\/\/secure.gravatar.com\/avatar\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g","caption":"\u7f8e\u901a\u793e"},"url":"https:\/\/pingtungtimes.com.tw\/?author=16"}]}},"_links":{"self":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/419001","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=419001"}],"version-history":[{"count":0,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/419001\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/media\/419002"}],"wp:attachment":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=419001"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=419001"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=419001"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}